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Advances in genomic technologies have facilitated the identification of novel tumor 
markers that predict prognosis. By making use of multiple genomic technologies, we 
describe here two methods that lead to the discovery of such markers in breast cancer:  
 
We sought novel targetable oncogenes by identifying secretory factors where 
overexpression is associated with cancer recurrence in multiple cohorts. Candidates were 
then assessed for phenotypic consequences by altering candidate gene expression in vitro. 
The top candidate, serine protease inhibitor Kazal-type 1 (SPINK1) was found to induce 
invasion, protect cells from apoptosis, and induce metastatic potential of cancer cells in 
mice. Downstream analysis revealed that SPINK1 caused resistance to apoptosis through 
the reduction of transcription and repressed activity of Bcl-2 in cancer cells.  
 
In a complementary project, we sought to identify candidate tumor suppressor genes in 
genomic regions that have exhibited a decrease in copy number and evidence for 
reduction to homozygosity in MCF-7. Genes in these regions coupled with silencing of 
transcription were identified. Based on association studies with patient prognosis, 
semaphorin 6D (SEMA6D) was discovered to function as a key player in a closely 
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Chapter 1: Introduction 
1.1 Oncogenes and Tumor Suppressor Genes 
The cell is a complex system that is tightly regulated and controlled. When this system is 
dysregulated, disease states are set in motion. Cancer is one such situation, when a 
particular cell evades regulatory mechanisms, proliferating in an uncontrolled manner to 
form a tumor mass. This is not usually attained by a single mutation, but a result of 
accumulated hallmark capabilities to overcome and evade various cellular regulatory 
signals (1, 2).  
One of the first suppressive signals that cancer cells need to overcome is growth 
suppression in order to develop into a chronic mass of tissue. Normal tissues control 
cellular division by secreting growth signals to promote growth; production of such 
signals halt, and growth inhibitors come into play when growth suppression is needed. In 
addition to growth signals, apoptosis takes over when defective or abnormal cells are 
detected. Such is also the case when there are excess cells or old cells that need to be 
removed. This balance of cell growth and death ensures a homeostasis and maintains a 
consistent cell number for optimal tissue functioning. In order for cancer cells to 
proliferate against regular cellular signals, they have to be “masters of their own destiny”, 
overriding cellular inhibitory and apoptotic signals to grow and proliferate continuously 
to form a tumor mass.  
Upon development of tumor masses, cancer cells need to develop the ability to 
move and invade through basement membranes into neighboring tissues and even 
metastasize to other parts of the body. This requires the cancer cells to first become 
motile, changing their shape and altering their interaction with the extracellular matrix 
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(ECM). During this transition, gene expression patterns are changed – E-cadherin, keratin 
and claudin levels are suppressed, while N-cadherin, SNAIL, F-actin and vimentin are 
overexpressed. As a result, the cells often become fibroblastic in nature -- a characteristic 
known as epithelial-mesenchymal transition (EMT) (1-4).  
To accumulate all these hallmarks of cancer, a pre-cancerous cell normally 
develops dysregulation of 2 main types of genes – oncogenes and tumor suppressor genes 
(5, 6).  
Oncogenes are typically mutated genes that contribute to cancer development. 
These genes, known as proto-oncogenes in an healthy individual, develop gain-of-
function mutations or are overexpressed by virtue of gene  amplification that result in a 
cell acquiring transformation characteristics (2, 5). Oncogenes typically induce 
uninhibited cellular proliferation by mimicking normal growth signals and bypassing cell 
cycle checkpoints, evade apoptotic signals, promote cellular migration and invasion into 
neighboring regions, and/or enable cells to survive without anchorage to the substratum.  
Tumor suppressor genes, on the other hand, inhibit cancer progression. These 
genes usually attenuate cell proliferation, block cell migrations, and may induce cell 
death. In order for tumor cells to grow, these unfavorable signals from tumor suppressor 
genes need to be suppressed, either by deletions, inactivating mutations or epigenetic 
silencing. As such, tumor suppressor genes often reside in genomic regions that are 
deleted, are homozygous with a loss of function mutation, or have epigenetic changes 





1.2 Integration of Oncogenic Signals in Cancer  
Unlike single gene disorders such as Achondroplasia and Huntington's disease, no single 
gene, except perhaps BCR-ABL for chronic myelogenous leukemia, is sufficient to 
generate a full blown malignant state (9-12). Instead, cancer develops as a result of 
multiple biochemical pathways and mechanisms that are disrupted and altered. For 
example, the loss of function of the adenomatous polyposis coli (APC) gene, which 
encodes a protein involved in cell adhesion and transcription, leads to the formation of 
premalignant adenoma. This single change increases the risk of developing colorectal 
cancer, but is insufficient to allow progression to adenocarcinoma. Instead, regulators of 
growth, adhesion and apoptosis such as KRAS, E-cadherin, SMAD4, INK4A and p53 
have to be mutated and altered in their expressions before colorectal cancer actually 
develops (13, 14). Such progressive accumulation of mutations as a pathway to a full 
blown cancer was enunciated in Vogelstein and Kinsler's well known "Vogelgram" of 
colon cancer progression (15).  
 Similarly, in breast cancer initiation and progression, multiple pathways have to 
be altered. This includes pathways that are involved in cell cycle regulation, cellular 
adhesion, cell migration, angiogenesis as well as apoptosis. Cell cycle regulators that are 
often altered in expression in breast cancer includes cyclin D1, p21, and TP53 which is 
inactivated in more than 50 percent of all human cancers (16-18). Growth factors and 
their receptors promote cell growth, and thus are often amplified in cancer. Estrogen 
receptors (ERs), for example, are overexpressed in over 70% of breast cancers, termed as 
“ER-positive”. This is due to estrogen binding to ER, which stimulates proliferation of 
mammary epithelial cells (19, 20). The amplification of human epidermal growth factor 
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receptor 2 (HER2), also known as ERBB2, results in increased aggressiveness in 15-20% 
of breast cancers. HER2 is a cell surface membrane-bound receptor tyrosine kinase that is 
involved in signal transduction pathways leading to cell proliferation and differentiation 
(21, 22). Epidermal growth factor receptor (EGFR), another member of the ErbB family 
of receptors, is also often highly expressed in breast cancer (23). Activated EGFR signals 
through MAPK, Akt and JNK pathways, leads to increased DNA synthesis, cell 
proliferation and cell migration in tumors with overexpressed EGFR (24).  These clinical 
findings have been corroborated by in vitro cellular experiments in co-transfection 
approaches originally pioneered by Harmut Land, and Robert Weinberg.  They found that 
transfection of a mutant ras gene (oncogene) or a myc oncogene individually into rat 
embryo fibroblasts did not transform these cells, but the combination of the two very 
efficiently transformed these primary cells (25, 26).  Human primary cells are more 
resistant to this form of transformation, requiring more cooperating genes -- mutant ras, 
SV40 and telomerase. This model of oncogene cooperativity became the theoretical basis 
for combinatorial mutational effects in cancer, whereby only progressive accumulation of 
multiple alterations in these biochemical pathways would lead to cancer (27, 28).    
In the past, oncogenes and tumor suppressor genes were discovered by the 
cloning of individual genes. Not only is this a slow and inefficient process, it also does 
not cater to the fundamentals of cancer—integrated pathway disruption. The cancer 
genome is characterized by single nucleotide polymorphisms, aberrant gene expression 
patterns and altered genomic structures (29). To account for this biological heterogeneity 
of tumor progression, we employed several high-throughput technologies to 
comprehensively analyze the cancer genome, and sought to discover driver oncogenes 
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and tumor suppressor genes that alter highly integrated biochemical pathways in a breast 
cancer cell. We validated the potential clinical importance of these aberrant genes by 
assessing the relationship between the expression of these genes and breast cancer patient 
survival from public domain data of expression microarrays.  These technologies are 
described below: 
 
1.3 Expression Profiling of the Cancer Transcriptome 
With the introduction of the DNA microarray platform and later RNA-sequencing (RNA-
seq), it has become feasible to simultaneously query the expression of thousands of genes 
with great precision. We have taken advantage of these two technologies to 
comprehensively study the aberrant gene expression patterns in breast tumors.  
Microarray gene expression profiling measures the RNA levels of previously 
identified genes to create a global picture of cellular activity. This allows for the genome-
wide identification of gene expression aberrations. Although measurement of proteins 
would be more biologically relevant than measurement at the mRNA level, microarray 
gene expression profiling remains the most widely documented database of tumor 
information as compared to proteomic profiling, thus the use of microarray gene 
expression profiles for survival analysis remains more clinically relevant. With such 
information available, genes that are clinically associated with patient outcome can then 
be identified. One such application is MammaPrint™, which measures levels of breast 
cancer biomarkers to predict patient prognosis (30).  
In parallel to the microarray-based approach, whole genome RNA-seq also allows 
for the quantification of transcriptional changes. Unlike expression arrays which take a 
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sample and representational approach to assessing gene expression, RNA-seq directly 
sequences putatively all components of the transcriptome; i.e. every exon and nucleotide. 
Thus, RNA-seq is not only more sensitive than microarray (partially due to much better 
signal to noise ratios and greater dynamic range), but it is also able to detect expression 
of unknown genes that have not been previously annotated on the microarray (31). As 
such, RNA-seq libraries are useful for the validation of transcriptional changes that may 
arise from novel structural variations in a genome not documented previously. In 
oncogene and tumor suppressor gene discovery, both microarray and RNA-seq 
information can be used in combination to confirm if amplified or deleted regions in the 
breast cancer genome are translated into enhanced or suppressed gene expressions 
respectively. 
 
1.4 Cartography of the Cancer Genome 
Changes in gene expression patterns in cancer can be caused by altered genomic 
structures. Therefore, by mapping and studying the genomic alterations that occur in 
breast cancer, we can further gather insights to mechanisms causing breast cancer. Along 
with the development of array-based approaches, DNA sequencing has also been used to 
measure gene expression and copy number changes. With the improvements in 
sequencing and bioinformatic technologies, it has become possible to use whole genome 
sequencing in the systematic analyses of genomic alterations in cancer (32, 33). Genomic 
paired-end tag sequencing (gPET, also known as DNA-PET) is a relatively new 
technology used for the detection of copy number and structural variations in a genome. 
It involves supervised sonication of DNA into 10kb fragments, from which short and 
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paired tags are extracted from the ends of the DNA fragments for ultra-high-throughput 
sequencing. The PET sequences can then be accurately mapped to the reference genome, 
thus revealing the identities of the PET sequences as well as identifying any structural 
variations present. By applying the PET technology on breast cancer genomes, regions 
that are amplified or deleted in breast cancer can be identified, facilitating the discovery 
of potential oncogenes and tumor suppressor genes (33, 34). SNP arrays, on the other 
hand, are useful for the identification of polymorphisms in a population, and are 
commonly used to discover SNP-based genetic linkage in diseases. Common examples of 
diseases that have different susceptibility from different SNP alleles include rheumatoid 
arthritis, diabetes mellitus type 1 and 2, and pancreatitis (35-40). In addition to 
genotyping, SNP arrays can also be used to detect copy number changes in a genome as 
well as identify regions displaying reduction to homozygosity (RTH). RTH is a form of 
allelic imbalance that can result from a random event. In a disease setting, this occurrence 
may be directed by the loss of the wildtype functional allele, while two copies of the 
mutant dysfunctional allele remains. This is a mechanism used commonly by cancer cells 
to silence genes that normally repress tumor progression. Examples of tumor suppressor 
genes inactivated in this manner include the retinoblastoma gene (Rb) and p53 in 
multiple cancer types, and BRCA1/2 in breast cancer (41-44). Hence, the identification of 
regions with RTH incidence rates higher than that expected of a random event may 






1.5 Aims of Thesis Research 
Intense efforts have been made in the past decades towards elucidating oncogenes and 
tumor suppressor genes in cancer. However, the discovery of these genes are often slow 
and difficult as the biochemical and molecular assays routinely used can only study one 
gene at a time. The main objective of this thesis is to integrate multiple genome-wide 
technologies to discover novel oncogenes and tumor suppressor genes that alter the 
closely integrated biochemical pathways in a cell resulting in breast cancer. In this thesis, 
we employed two different strategies that take advantage of various high-throughput 
technologies to scan for oncogenes and tumor suppressor genes.   
 For the first strategy, we aimed to discover novel oncogenes that were associated 
with poor patient prognosis by overlapping microarray gene expression profiles with 
clinical information. Potential oncogene candidates were filtered for only secreted factors 
and cell surface receptors for their potential targetability, as well as based on their 
novelty. The gene, SPINK1, turned out to be the top candidate from this strategy which 
we describe in detail in Chapter 2. We went on to characterize SPINK1 and showed that 
it is a potential oncogene which plays a significant role in breast cancer progression. In 
Chapters 3 and 4, we showed with knockdown, overexpression and treatment with 
recombinant protein that SPINK1 induces cellular invasion, promotes metastasis, blocks 
apoptosis and enhances resistance to commonly used chemotherapeutic drugs. 
 In Chapter 5, we integrated the information gathered from genomic and 
transcriptomic studies of the breast cancer cell line, MCF-7, to discover novel tumor 
suppressor genes. RTH regions were identified using the SNP array, which were then 
overlapped with copy number information from both the SNP array as well as gPET 
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analysis. Deleted regions that were coupled with regions of RTH were selected, and 
further filtered for silenced expression by integrating RNA-seq into the analysis. Finally, 
the list of candidate genes were compared to microarray gene expression profiling and 
clinical information of 760 breast tumor cases to select for the potential candidate tumor 
suppressor genes in breast cancer. The top candidate from this pipeline, SEMA6D, was 
further validated in Chapter 6, where the re-expression of SEMA6D was shown to be 
detrimental to the growth of breast cancer cells.  
 This thesis highlights the power of integrating multiple genomic technologies in 
the identification of novel oncogenes and tumor suppressor genes. It allows for the 
discovery of important genes that lie in the hub of highly integrated biochemical 















Chapter 2: Discovery of Novel Targetable Oncogenes in Human Breast Cancer 
 
Introduction  
Breast cancer is the most prevalent cancer in women and the second highest 
cancer killer in women after lung cancer. In 2010, over 200 000 women in the United 
States of America alone are expected to be diagnosed with invasive breast cancer, and 
will account for about 15% of all cancer deaths (46). Current therapy options for breast 
cancer include surgery, chemotherapy, radiotherapy, hormonal therapy and gene-targeted 
therapies.  
The primary goal of novel anticancer drug design is to directly target specific 
molecular aberrations or mutations found almost exclusively in tumor cells, thereby 
improving cancer treatment efficacies and reducing cytotoxicity in normal cells. 
Advances in molecular biology have facilitated the identification of tumor markers that 
not only predict prognosis and therapeutic responses, but may also function as potential 
therapeutic targets (47). The rates at which tumor cells proliferate and spread are not 
affected solely by the inherent characteristics of the tumor cells, but are also influenced 
by the tumor microenvironment from which the tumor cells receive signals from. These 
signals are usually transmitted into the tumor cells through cell surface receptors to result 
in the regulation of proliferation, survival, motility as well as angiogenesis. As a result, 
extracellular proteins and cell surface receptors are not only candidates for targeted 
cancer therapy, but may be preferred targets due to their accessibility to drugs (48). 
Current target therapies aim at regulating apoptotic pathways, angiogenesis and cell cycle 
progression (49). One prominent example of a targeted cell surface receptor is the human 
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epidermal growth factor receptor 2 (HER2), a member of the human epithelial growth 
factor receptor family, which is known to be amplified in 20-25% of human breast cancer 
and is associated with poor prognosis (50-52). Patients given anti-HER2 drugs such as 
Trastuzumab display improved prognosis, but majority develop resistance within a year 
of treatment (53, 54). This is a common problem amongst current drugs used in breast 
cancer treatment, hence making it essential to discover new targets.  
Motivated by a need to discover new targets for breast cancer therapy, we 
developed a high-throughput pipeline for the discovery and validation of novel 
oncogenes in human breast cancer that focused on extracellular proteins, growth factors 
or cell surface receptors that could possibly be easily targetable using antibody-based or 
small molecule therapies. Such therapies are known to exhibit reduced toxicity as 
compared to intracellular targets. Towards this end, we mined the expression profiles of 
760 primary breast cancers from multiple patient cohorts to select genes encoding 
extracellular proteins, secreted growth factors or cell surface receptors that are 
consistently associated with poor patient survival. We then investigated their oncogenic 




Microarray analysis reveals 9 potentially targetable candidate oncogenes. 
To discover novel targetable oncogenes in breast cancer, we developed a whole-genome 
data-mining approach that leverages large independent microarray studies for the 
systematic discovery of genes correlated with distant metastasis-free survival (DMFS) of 
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patients. In an initial screen involving 760 tumors derived from four independent breast 
cancer cohorts (55-58), we performed Cox proportional hazards regression on each of 
44,928 gene probe sets (Affymetrix U133A and U113B Genechips) to identify candidate 
oncogenes by their statistically significant and reproducible associations with metastatic 
recurrence (Figure 2.1). The genes were then cross-referenced with the Gene Ontology 
database (www.geneontology.org) to identify all metastasis-associated genes encoding 
known and predicted transmembrane receptors and secreted growth factors. A literature 
search was further performed on the potentially targetable candidate oncogenes identified 
from our GO analysis, to filter for only novel genes that have not been previously shown 
to be associated with breast cancer oncogenesis (Table 2.1). 
 
 
Figure 2.1: Schematic diagram of candidate oncogene identification from expression 
profiling. (A) Heatmap of genes across 4 independent breast cancer cohorts, stratified by 
gene expression above and below mean (=760). (B) Example of kaplan-meier plot 
showing potential oncogene displaying poorer prognosis in patient group with above 
mean expression. (Note: Analyses were performed by Dr Lance D. Miller, Department of 
Cancer Biology, Wake Forest University School of Medicine)  
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Table 2.1: List of candidate oncogenes. 
 
 
Phenotypic assays reveal SPINK1 as the most prominent oncogene candidate. 
To assess the oncogenic properties of these candidate oncogenes, we set up a pipeline for 
the screening of standard oncogenic phenotypes. To select an appropriate cell line to 
work with, expression levels of all genes were measured across a panel of breast cancer 
cell lines. There were relatively similar levels of expression of all candidate genes in all 
the cell lines tested (data not shown). We thus transiently attenuated the candidate gene 
levels in 2 well characterized and assayable breast cancer cell lines MDA-MB-231 and 
MCF-7 using siRNA. siRNAs were commercially available for 8 of the 9 candidate 
oncogenes, and the efficacy of 3 siRNAs per gene were tested and checked on both breast 
cancer cell lines via RT-PCR. 7 out of 8 candidate oncogene knockdowns were 
successful, with only PNLIPRP2 unable to be knocked down with all 3 commercial 
siRNAs used (Figure 2.2). Using the siRNA that produced the best knockdown for each 
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gene, phenotypic assays were carried out on both breast cancer cell lines to assess their 
roles in cell proliferation, apoptosis and attachment-independent colony formation 
(Figures 2.3 – 2.5). Results obtained from both cell lines were comparable, and a 
summary of all assays carried out is shown in Table 2.2. From this initial screen, SPINK1 
emerged as the most prominent candidate oncogene.  
 
Figure 2.2: Real-time PCR of candidate oncogenes upon transient siRNA knockdown. 3 
different siRNAs were commercially obtained per gene, and transfected into MCF-7 and 
MDA-MB-231 cells for 48 hours before RNA was harvested for real-time PCR analysis. 
Graphs show the gene expression change obtained with the most effective of the 3 




Figure 2.3: Proliferation of candidate oncogenes upon siRNA knockdown. (A, B) Effect 
of siRNA knockdown on cellular proliferation. Assay was setup 48 hours after siRNA 
knockdown, and measured daily using WST for 5 days. Readings were normalized to the 




Figure 2.4: Levels of activated PARP and caspase-3 with knockdown of candidate 
oncogenes. Cells were transfected with siRNA (50nM) in a 96-well format for 48 hours, 
treated with 5-FU (0uM, 75uM, 100uM), fixed 24 hours later, probed with the 






Figure 2.5: Soft agar colony formation assay. Cells were plated 48 hours post-












Table 2.2: Summary of candidate oncogene phenotypic screen through transient siRNA 
knockdown.  
 
Darker blues represent strong loss of oncogenic properties upon loss of gene, while 




In this study, using genome-wide profiling of breast tumors from multiple cohorts and 
clinical association with patient prognosis, we looked for potential oncogenes that are 
associated with poor distant metastasis-free survival. We identified 9 novel candidate 
oncogenes as possible drivers of aggressiveness in breast cancer. We observed the effects 
of transient knockdown of these genes via siRNA, measuring their effects on classical 
oncogenic phenotypes including cellular proliferation, anchorage-independent growth 
and cellular apoptosis. Although knockdown of 7 of these candidate oncogenes resulted 
in a decrease in cellular proliferation, only loss of TEX264, SPINK1 and LOC401115 
reduced the ability of cancer cells to grow without anchorage. Further, cells entered 
apoptosis only upon loss of SPINK1 or LOC401115. Through these assays, we identified 
SPINK1 to be the most prominent candidate oncogene that when knocked down resulted 
in stark reduction in both cellular proliferation and the ability of cells to grow without 
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anchorage, and further induced cellular apoptosis. Hence, through siRNA screen, we 












Chapter 3: Validation of Top Oncogene Candidate, Serine Protease Inhibitor  
Kazal Type 1 (SPINK1)  - Soon WW et al. EMBO Mol Med (In Press) 
 
Introduction  
SPINK1 is a small secreted protein of 56 amino acids after cleavage of a 23 amino acid 
secretory signal peptide at the N-terminus, originally isolated from human pancreatic 
juice. Its primary function is trypsin inhibition in the pancreas and small intestines (59), 
and is known to be strongly associated with pancreatitis (36, 60). Inactivation of SPINK1 
in the pancreas results in autophagy of exocrine pancreatic cells. Multiple variants of 
SPINK1 that lead to a loss-of-function have been previously shown to be a strong causal 
factor for chronic pancreatitis possibly because of the loss of trypsin inactivation (36, 60). 
Interestingly, mice deficient in SPINK3, the mouse homolog of human SPINK1, die due 
to excessive autophagy of the pancreatic acinar cells. Similar autophagy has been 
observed in Hydra upon silencing of the SPINK1-homolog. In liver cells, Hepatitis B and 
C viruses induce expression of SPINK1, thereby protecting liver cells from serine 
protease dependent cellular apoptosis (SPDCA) (61). Taken together, SPINK1 appears to 
play an important role in cell survival and prevention of apoptosis.  
SPINK1 was first discovered in the urine of ovarian cancer patients, but has since 
been found to be strongly associated with poor prognosis in several types of cancers 
including that of the prostate, ovary, bladder, pancreas and colon (62-65). In some cell 
lines derived from these tissue types, SPINK1 has been shown to enhance proliferation 
and cell invasion in vitro. It has been suggested that SPINK1 induces cellular invasion 
through pathways such as phosphoinositide 3-kinase (PI3K), Rho-like GTPases and 
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protein kinase C (PKC). This process appears to require its trypsin inhibitory property as 
a single mutation at the trypsin binding site fails to induce cellular invasion of colon 
cancer cells (64). However, when we treated SPINK1 to breast cancer cells, there was 
only enhanced cell invasion but not proliferation of the breast cancer cells. Further, 
mutant SPINK1 with a disrupted trypsin-binding site was still able to induce cellular 
invasion of breast cancer cell lines, as opposed to what was discovered in colon cancer 
cells. With discrepancy in results obtained by us and the literature, we investigated 
further to see if this inconsistency was due to different tissue types. By comprehensively 
altering SPINK1 levels using siRNA-mediated knockdown, stable overexpression and 
exogenous application of SPINK1 to several breast cancer cell lines, we show that 
SPINK1 affects multiple steps of breast cancer progression including invasion, motility, 
metastasis, cellular survival, and resistance to drug-induced apoptosis. Further, we show 
that both SPINK1 RNA and protein levels are predictive of patient survival specifically 




SPINK1 transcript levels are positively correlated with breast cancer metastasis. 
Of the small number of candidate oncogenes we identified in Chapter 2, SPINK1 was 
observed to be positively correlated with metastatic recurrence in all four cohorts. We 
next extended our meta-analysis to all publicly available breast cancer expression array 
datasets (annotated for survival outcomes) (55-58, 66-70) as of 2009, and found that the 
expression of SPINK1 was reproducibly correlated with metastatic recurrence in 8 of 10 
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breast cancer studies (Overall Hazard Ratio=1.19; Confidence Interval [1.10, 1.28]; 
p<1E-05) (Figure 3.1).  
 
 
Figure 3.1: Meta-analysis displaying the association of SPINK1 expression with poor 
DMFS across multiple cohorts (p<1E-05). 10 publicly available datasets were analyzed 
and are listed on the Y-axis of the graph. The dotted line represents hazard ratio of 1. 
 
SPINK1 associates with poor prognosis mainly in ER+ breast cancer.  
To study the association of SPINK1 with prognosis in specific subtypes of breast cancer 
classified by Perou et al. (71), we extended the analyses to a ‘mega cohort’ of 2,034 
publicly available breast cancer expression profiles from 15 independent cohorts (Table 
3.1). We found that SPINK1 expression was linearly associated with poor DMFS in ER+ 
patients, but did not significantly correlate with the survival of the ER-negative (ER-) 
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group (Figure 3.2). However, stratification of ER- patients into 10 groups based on the 
intensity of SPINK1 expression showed that very high SPINK1 levels marginally 
displayed a trend towards poor prognosis in ER- patients (Figure 3.2 and 3.3). 
Interestingly, SPINK1 did not show differential expression between ER+ and ER- 
samples, nor was its expression biased in any intrinsic molecular subtypes of breast 
cancer (Figure 3.4). Further, SPINK1 levels did not correlate with prognosis of any 
intrinsic subtypes of breast cancer (Table 3.2).  
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Table 3.1: Data table of cohorts comprising the breast cancer microarray “Super Cohort”. 
 
 (Note: Data was generated by Dr Michael A. Black, Department of Biochemistry, 




Figure 3.2: Kaplan-Meier curves demonstrating the association of SPINK1 expression 
with patient prognosis in ER+ and ER- cohorts. (A) KM-plots of SPINK1 expression in 
all samples (left panel), ER-negative cases (middle panel) and ER-positive cases (right 
panel). Samples are divided into 2 groups, above mean SPINK1 expression (red) and 
below mean SPINK1 expression (green). Prognosis is measured with distant metastasis-








Figure 3.3: Kaplan-Meier curves demonstrating the association of extreme SPINK1 
expression with patient prognosis in ER+ and ER- cohorts. (A) KM-plots of ER+ versus 
ER- breast cancers irrespective of SPINK1 expression. (B and C) KM-plots of SPINK1 
expression in ER-negative cases (B) and ER-positive cases (C). Samples are divided into 
ten groups according to SPINK1 expression, and KM-plots were drawn with the top 10% 
expressors of SPINK1 (red) and bottom 10% expressors of SPINK1 (green). Prognosis is 
measured with distant metastasis-free survival (years). (Note: Analyses were performed 





Figure 3.4: Boxplots of SPINK1 expression across different subgroups of breast cancer. 
(A) Expression distribution of SPINK1 against ESR1 levels. (B) Expression distribution 
of SPINK1 across different molecular subtypes of breast cancer. (Note: Analyses were 
performed by Dr Lance D. Miller, Department of Cancer Biology, Wake Forest 
University School of Medicine) 
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Table 3.2: Subgroup analysis for associations of SPINK1 expression levels with DMFS 
by Cox Proportional Hazards Regression. 
  
 (Note: Analyses were performed by Dr Lance D. Miller, Department of Cancer Biology, 







SPINK1 expression differs in normal and breast tumor tissue.   
To investigate the subcellular localization of the SPINK1 protein in both benign and 
malignant breast tissues, we immunostained 98 clinically annotated cores on a tissue 
microarray using an anti-SPINK1 antibody. Normal pancreas served as a positive control 
and specificity of the staining was evaluated by pre-neutralizing the antibody with 
SPINK1 protein (Figure 3.5). The expression of SPINK1 was negligible in normal breast 
tissue, but most tumors were immunoreactive (95%) (Figure 3.6A, B, C). This suggested 
that SPINK1 is probably expressed early in tumor development and is also present in 
advanced disease. We then analyzed SPINK1 protein levels in 81 breast cancer samples 
annotated with patient survival data.  High SPINK1 levels correlated with overall lower 
disease-free survival. Upon sub-division of patients into ER+ and ER- cohorts, this 
correlation was most significant in the subset of ER+ breast cancer cases (Figure 3.7), 
supporting our findings of SPINK1 positive association with poor prognosis at a 
transcript level. Moreover, SPINK1 expression did not associate with grade, age, 
ethnicity, stage and cERBB2 (Table 3.3, 3.4). Interestingly, SPINK1 localization seemed 
to vary across tumor tissue, with some expressing SPINK1 in the cytoplasm and others in 
the nuclei. To confirm that this nuclear localization is not an artifact of the 
immunohistochemical staining of paraffin processed tissue, we performed 
immunofluorescence on MDA-MB-231 cells treated with soluble recombinant SPINK1 
bearing a 6Xhis tag.  Using an antibody against the tag as well as an antibody against 
SPINK1, we confirmed that exogenously applied SPINK1 localized in the nucleus within 





Figure 3.5: Optimization of SPINK1 immunohistochemical staining. (A) 
Immunohistochemistry of SPINK1 in various tissue types. Normal pancreatic tissue is 
used as a positive control for the optimization of the protocol. (B) Neutralization of 
pancreatic SPINK1 IHC staining with 24hour preincubation of anti-SPINK1 antibody 




Figure 3.6: SPINK1 expression in normal breast and breast tumors. SPINK1 expression 
was negligible in 10 normal breast cores. (A, panels a-h). (B) This panel shows 
representative cores from the commercial breast tissue microarray. As shown, invasive 
ductal carcinomas were positive but displayed various levels of SPINK1. (B, panels a-h). 
(C) SPINK1 nuclear staining was restricted to the breast tumor cells (green arrow) but 
was completely absent in adjacent normal cells (red arrow). (D) Localization of SPINK1 
in vitro. MDA-MB-231 cells were treated with SPINK1-CM and uptake of SPINK1 (if 
any) was studied using 2 antibodies. Nuclear staining was observed in cells after 12-24 
hrs of SPINK1 treatment, recapitulating staining observed in primary tumors (Blue: 





Figure 3.7: Kaplan-Meier curves demonstrating the association of SPINK1 protein levels 
with patient prognosis. KM-plots of SPINK1 protein expression in tissue microarrays in 
all samples (left panel), ER-negative cases (middle panel) and ER-positive cases (right 
panel). Prognosis is measured with disease-free survival in months. (Note: Analyses were 
performed by Dr Manuel Salto-Tellez’s team, in particular Chee Wee Ong, Cancer 




















Table 3.4: Univariate association between SPINK1 expression and clinicopathological 
features. 
 
 (CI: Confidence Intervals; OR: Odds Ratio; P: p significance for chi-squared test) (Note: 
Analyses were performed by Dr Manuel Salto-Tellez’s team, in particular Chee Wee Ong, 
Cancer Science Institute, National University of Singapore) 
 
Loss of SPINK1 results in reduced cell survival.  
To investigate the oncogenic properties of SPINK1, we attenuated SPINK1 transcript 
levels by siRNA in the breast cancer cell lines MCF-7 and MDA-MB-231, and conducted 
assays to detect phenotypic changes in cell proliferation, motility, invasiveness and 
anchorage-independent growth. Each of the 3 SPINK1-targeted siRNA constructs 
reduced SPINK1 expression in MCF-7 and MDA-MB-231 cells by >50%, with C2 
siRNA being the most efficient (>95%) (Figure 3.8A). Changes in SPINK1 protein levels 
upon knockdown could not be measured via western blot due to inability of the SPINK1 
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antibody to detect endogenous levels of SPINK1. Consistent with a threshold effect, C2 
siRNA led to the most significant reduction of proliferation for both MCF-7 and MDA-
MB-231 (Figure 3.8B), whereas C1 and C3 siRNAs, displayed marginal phenotypes. We 
posited that the observed decrease in proliferation resulting from siRNA-mediated 
knockdown of SPINK1 could reflect either cell cycle arrest or apoptosis. Therefore, we 
studied the activation of apoptotic markers PARP and caspase-3 using a cell-based 
immunofluorescence assay in SPINK1-knockdown cells. Loss of SPINK1 induced 
activation of both PARP and caspase-3 in MDA-MB-231 (p<0.05, Figure 3.8C, left panel) 
and MCF-7 cells (Figure 3.8C, right panel). Taken together, the apparent decrease in cell 
proliferation upon complete loss of SPINK1 was due to the induction of cellular 








Figure 3.8: Phenotypic assays upon siRNA-knockdown of SPINK1. (A) siRNA-
mediated knockdown of SPINK1 using three different siRNAs in breast cancer cell lines 
MCF-7 and MDA-MB-231. SPINK1 expression is detected via RT-PCR. (B) Effect of 
SPINK1-kd on cell proliferation in MDA-MB-231 (left panel) and MCF-7 (right panel). 
(C) Activated PARP and Caspase-3 upon siRNA-mediated knockdown of SPINK1 is in 
MDA-MB-231 (left panel) and MCF-7 (right panel).  
 
Rescue of siRNA mediated phenotype(s) by exogenous SPINK1.  
To determine the specificity of our SPINK1 siRNA knockdowns by phenotypic rescue, 
we sought to produce recombinant SPINK1 using bacteria. 7 different vector constructs 
containing SPINK1 were made, of which 1 successfully produced GST-tagged SPINK1 
in large amounts (Table 3.5, Figure 3.9A). SPINK1 was purified with the GST-tag, and 
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the identity of the product was confirmed via TEV-cleavage and western blot (Figure 3.9). 
However, when the protein was tested for functionality using the invasion assay, we 
found that this source of SPINK1 was not functional (data not shown). This could be due 
to misfolding of SPINK1 in the bacteria, as SPINK1 has 3 disulfide bridges that need to 
be formed in close proximity of each other.  
We thus switched to use mammalian and insect protein production systems, which 
are known to be better at producing functional proteins that require post-translational 
modifications and specific folding. Two sources of recombinant SPINK1 were generated 
by over-expressing SPINK1 in MCF-7 (SPINK1-CM) and SF9 insect cells 
(SF9spink1CM) (Figure 3.10). Conditioned media was collected from both sources, as 
well as from cells transfected with empty vector as controls (vector-CM and SF9vecCM, 
respectively). Addition of SPINK1-CM to cells transfected with C2siRNA resulted in 
decreased TUNEL positive cells in this group as compared to cells treated with vector-
CM (Figure 3.11A). Further, treatment of C2siRNA cells with SPINK1-CM resulted in 
BrDU labeling showing that these cells survived and could subsequently divide (Figure 
3.11B). These results confirm the specificity of the siRNA used as well as the 
functionality of the recombinant SPINK1. Interestingly, neither MCF-7 cells over-
expressing SPINK1, nor various breast cancer cell lines treated with SPINK1-CM, 
showed increased proliferation (Figure 3.12). This further supports the notion that 
SPINK1 is probably an important survival factor rather than a potent growth inducer in 














Figure 3.9: Production of SPINK1 using bacteria. (A) Diagram of SPINK1 construct 
with a 5’GST tag, removable with TEV. (B) Silver stain and western blot of SPINK1 
across timepoints after TEV cleavage. (C) Western blot of SPINK1 in different elutes 








Figure 3.10: Conditioned media production of SPINK1 using mammalian and insect 
baculoviral systems. (A) Diagram of SPINK1 construct with a 3’6XHis tag. Western blot 
of conditioned media collected from MCF-7 (B) and SF9 (C) overexpressing SPINK1. 
For MCF-7, 9 individual clones were picked, and empty vector clones were pooled. 
Clone 9 was used to produce SPINK1-CM for experiments. For SF9, 2 different 
concentrations of conditioned media were collected from both SPINK-overexpressing 






Figure 3.11: Rescue experiments with recombinant SPINK1 (A) TUNEL assay 
demonstrating the impact of SPINK1 on cell apoptosis. Loss of SPINK1 in MDA-MB-
231 results in an increase in DNA fragmentation, and this effect can be rescued with the 
addition of exogenous SPINK1 (B) BrDU proliferation assay of MDA-MB-231. 
Incorporation of BrDU upon SPINK1-kd, and rescued with the addition of bioactive 






Figure 3.12: Effect of SPINK1 on cell proliferation (A) Proliferation of multiple breast 
cell lines upon addition of SPINK1-CM in either 1x or 5x dilution. BrDU labeling is 
measured 24 hours after exogenous application of SPINK1-CM. (B) Proliferation of 
SPINK1-overexpressing MCF-7 cells over 5 days. 
 
SPINK1 augments drug resistance.  
Given the evidence that SPINK1 is a survival factor in breast cancer cell lines, we asked 
whether SPINK1 could increase cellular resistance to anti-cancer drugs in either an 
autocrine or paracrine fashion. First, we treated MCF-7 cells stably overexpressing 
SPINK1 with increasing concentrations of five commonly used chemotherapeutic drugs, 
5-fluorouracil (5-FU), suberoylanilide hydroxamic acid (SAHA), tamoxifen (TAM), 
adriamycin (ADR) and etoposide (VP16). These cells were significantly more resistant to 
chemically-induced apoptosis as compared to control cells, as measured with PARP (left 
panel) and caspase-3 (right panel) activation levels (Figure 3.13A-E). Next, we pretreated 
MCF-7 parental cells with exogenous SPINK1-CM before inducing apoptosis with 5-FU. 
Strikingly, 5-FU-mediated cell death was largely abrogated by pretreatment with 
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SPINK1-CM compared to cells pre-treated with control media (vector-CM) (Figure 
3.13F-G). Therefore, increased levels of SPINK1, both by autocrine and paracrine 






Figure 3.13: Induction of cell resistance to chemically-induced apoptosis. Activation of 
PARP (left panel) and caspase-3 (right panel) was measured in vector control (white bars) 
and SPINK1 overexpressing cells (black bars) following 24hr of exposure to varying 
concentrations of (A) 5-FU, (B) SAHA, (C) VP16, (D) TAM and (E) ADR. Cells over-
expressing SPINK1 showed reduced sensitivity to all tested chemotherapeutic drugs.  (F 
and G) Parental MDA-MB-231 cells sensitive to the drugs were pretreated with SPINK1-
CM recombinant SPINK1 from MCF-7 (F) and SF9 (G) with the respective control 
conditioned media, and then exposed to various doses of the drug. Apoptosis was 
measured via activated PARP (left panels) and activated caspase-3 (right panels) levels. 
(* p<0.005; ** p<0.05; *** p<1E^-05) 
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SPINK1 leads to increased invasion of breast cancer cells.  
In previous RNA depletion studies, transient loss of SPINK1 expression resulted in an 
apparent decrease in cell motility and cell invasiveness in MDA-MB-231 and BT549 
cells. Further, the anchorage independent growth of MCF-7 cells was severely 
compromised (Figure 3.14). These effects may be primarily due to induction of apoptosis 
via the loss of SPINK1. We hypothesized that the addition of soluble SPINK1, however, 
may induce a wider range of cellular phenomena. As shown in figure 3.15A, SPINK1-
CM increased invasion by 1.5-2.5 fold across multiple breast cell lines: MCF-7, MDA-
MB-231, BT549, and the non-invasive MCF10A cells. Moreover, we found that this 
induction of cellular invasion can be immunoneutralized by the anti-SPINK1 antibody 
from MoBiTec (Figure 3.15B) suggesting that the SPINK1 present in the conditioned 
media is bioactive. Figure 3.15C shows that the decrease in MDA-MB-231 invasiveness 
by SPINK1-knockdown can be rescued with recombinant SPINK1. To test if 
invasiveness of MDA MB231 cells was similarly affected in vivo, we injected MDA-
MB-231 cells over-expressing SPINK1 into the tail-vein of Balb/c nu/nu mice. Figure 
3.15D shows that SPINK1 expression led to increase in both the number and size of 
metastatic lesions in the mouse lung. Mice injected with MB231-vector cells had only 
4.1%±2.7 lesions larger than 200um, while MB231-SPINK1 overexpressing cells gave 
rise to significantly larger lesions with 24.8%±8.5 larger than 200um (p<0.05). The 
MB231-SPINK1 overexpressing cells also formed almost 3-fold more lesions than that of 
the control cells (p<0.05). These data suggest that breast tumor cells with high SPINK1 
expression may metastasize more efficiently that those expressing lower amounts of 
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SPINK1. No overexpression experiments were carried out with the soft agar colony 
formation assay due to high background levels of colony formation with MCF-7 cells.   
  
Figure 3.14: Phenotypic assays on breast cancer cell lines upon loss of SPINK1. (A, B) 
Effect of SPINK1 knockdown on the migration and invasion of MDA-MB-231 and 
BT549 cells. Number of cells migrated and invaded were counted 48 hours after assay 
setup. (C) Soft agar anchorage-independent growth assay on MCF-7 cells upon loss of 
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SPINK1. Colonies were stained and counted 21 days after plating. (* p<0.005; ** p<0.05; 
*** p<1E^-05) 
 
Figure 3.15: SPINK1 induces cellular invasion in vitro and in vivo. (A) Effect of 
SPINK1-CM on invasion in four breast cell lines. The cell lines used are listed on the X-
axis. For each cell line, the total number of cells that invaded after 24 hrs in response to 
vector-CM was denoted as 100%. Response to SPINK-1 was normalized to vector-CM 
for each cell line and expressed as percentage relative to control as shown on the y-axis. 
(B) (left panel) Effect of SF9spink1CM and immunoneutralization. (white bars- 
SF9vecCM; black bars- SF9spink1CM diluted 10x; checkered bars- conditioned media 
with addition of neutralizing antibody against SPINK1) (right panel) Effect of 
SPINK1CM and immunoneutralization. (white bars- vecCM; gray bars- SPINK1CM 
49 
 
diluted 10X; black bars- SPINK1CM diluted 5x; checkered bars- conditioned media with 
addition of neutralizing antibody against SPINK1) (C) Cell invasion assay. Loss of 
invasion upon SPINK1 siRNA treatment, and rescued with SPINK1-CM. (D) Tail vein 
xenograft assay. MDA-MB-231 vector-control cells or SPINK1-overexpressing cells 
were injected intravenously into 3 mice each, and total lung metastases were counted 12 
weeks later. (* p<0.005; ** p<0.05) 
 
SPINK1 overexpression does not lead to transformation of cells. 
An oncogene is a gene that when overexpressed, leads to cellular transformation 
indicative of oncogenesis. A classical transformation assay is that of NIH-3T3 cells, 
where normal NIH-3T3 cells grow in a monolayer, while transformed NIH-3T3 cells 
form foci within 1-2 weeks of induced oncogene expression. By setting up the NIH-3T3 
transformation assay using constitutively-active Ras as a positive control, we observed 
that SPINK1 overexpression was unable to induce full transformation of NIH-3T3 cells 
(data not shown). This result was further confirmed by a 3-dimensional assay (3D assay) 
of MCF10A cells. In this setup, MCF10A cells normally grow and form 3D hollow, 
spherical structures that are indicative of polarization and differentiation of normal breast 
epithelial cells. Stable overexpression of an oncogene, such as Myc (MCF10A-Myc), 
would result in MCF10A forming irregularly-shaped structures with a solid core and no 
polarization of the cells within each structure. Using a lentiviral construct to stably 
overexpress SPINK1 in MCF10A (MCF10A-SPINK1) with an empty vector as a control 
(MCF10A-vec), we sought to find out if SPINK1 would result in such oncogenic changes 
of non-tumorigenic MCF10A cells. We found that phospho-ERM was highly enriched in 
50 
 
MCF10A-SPINK1, similar to that in MCF10A-Myc, as compared to MCF10A-vec. 
However, the 3D hollow structures formed with MCF10A-SPINK1 continued to retain 
polarity, indicating that the cells were not transformed. Similar results were obtained with 
MCF10A regularly treated with external sources of SPINK1, indicating that SPINK1 is 
non-transformative in both autocrine and paracrine settings (data not shown). With these 
same MCF10A-SPINK1 cells, we also found that SPINK1 overexpression does not 
enhance the ability of MCF10A cells to grow independently of anchorage, a phenotype 
observed with other classical oncogenes such as Myc. Thus, we conclude that SPINK1 




In this study, using genome-wide profiling of breast tumors from multiple cohorts as well 
as validation by cell-based phenotypic assays, we identified for the first time that 
SPINK1 is a biological driver of aggressiveness in breast cancer. With the exception of 
gastric malignancies, high levels of SPINK1 expression have been associated with poor 
prognosis in multiple cancer types such as prostate cancer, liver cancer, ovarian cancer 
and bladder cancer, (62-65, 72-74). However, this association has not been documented 
in breast cancer. Tomlins et al. showed association of SPINK1 expression in ETS-
rearrangement negative prostate cancer and proposed that loss of SPINK1 attenuates 
invasiveness (63). In this report, we extend the clinical importance of SPINK1 expression 
to breast cancer. All breast cancer cohorts analyzed display a positive association of 
SPINK1 expression with poor outcome. Further analysis of SPINK1 in 2,034 breast 
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tumors from 15 independent cohorts revealed that SPINK1 is significantly associated 
with poor prognosis only in ER+ tumors but not in ER-. However, SPINK1 expression 
does not correlate with ER expression levels, suggesting that SPINK1 could possibly 
induce similar phenotypic effects regardless of ER status in tumors. However, the 
association of SPINK1 with DMFS in ER- tumors could be masked by other oncogenic 
pathways specific to ER- tumors that predispose to metastatic relapse, thus SPINK1 may 
not be a primary driver of metastasis in ER- disease. Accordingly, in tumors with low 
SPINK1, other oncogenic pathways may be driving metastasis thus lowering the survival 
curve. 
This association is recapitulated at the protein level, in a panel of clinically 
annotated breast tumors, where high SPINK1 expression was consistently and 
significantly associated with poor prognosis of ER+ rather than ER- tumors. Despite 
SPINK1 being a secreted extracellular protein, we observed unexpected subcellular and 
nuclear localization of SPINK1, not only in a time-dependent manner in cell lines in vitro, 
but also in the nuclei of primary tumors. Soluble secreted growth factors such as the 
epidermal growth factor and fibroblast growth factor, are transported into the nucleus and 
are known to mediate transcription (75). However, the implications of such nuclear 
localization in breast cancer progression remain unclear, and will need further study.  
Recombinant SPINK1 has been described to have opposing effects that are cell 
type specific, augmenting  cell proliferation in gastric and pancreatic (76, 77) but not in 
prostate cancer cell lines (63). Functionally, SPINK1 serves as a motility factor in various 
colon, prostate and gastric cancer cell lines and this effect can be attenuated in colon 
cancer cell lines by PI3K, PKC and Rho GTPase inhibitors (63, 64, 76). 
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To determine cellular functions of SPINK1 in breast cancer, we analyzed the 
phenotypic effects of SPINK1 attenuation, recombinant SPINK1 treatment and SPINK1 
over expression, and observed its sub-cellular localization. Our results strongly suggest 
that SPINK1 does not induce proliferation as was previously thought, but rather 
augments both cell survival and cancer cell motility and invasion. Such decoupling of 
growth from the conjoint phenotype of invasion and survival has been well documented 
in another cancer-associated ligand–receptor system such as the GAS6 ligand with its 
cognate receptor, the tyrosine kinase, AXL (78). We have extended our findings to show 
that recombinant SPINK1 not only enhances cell survival, but also induces resistance to 
apoptotic induction by common cytotoxic agents: SAHA, 5-FU, TAM, ADR and VP16.  
The overexpression of SPINK1 in non-tumorigenic MCF10A and NIH3T3 cells 
did not induce transformation of the cells. Further, in mouse xenograft assays, SPINK1 
failed to induce invasiveness in non-metastatic MCF-7 cells injected in the flank of 
Balb/c nu/nu mice, nor did the SPINK1 over-expressing cells form significantly larger 
primary tumors in mice as compared to control cells (data not shown). However, SPINK1 
expression greatly augmented dissemination and extravasation of MDA-MB-231 cells to 
mouse lungs in a tail-vein injection assay. These data suggest that in breast cancer, 
acquisition of SPINK1 expression may not be the initiating event in tumor formation and 
metastasis, but it certainly promotes tumor progression. 
Although SPINK1 itself is unable to initiate the process of oncogenesis from non-
tumorigenic cells, it undoubtedly increases the aggressiveness of tumor cells by inducing 
cellular invasion and evading apoptosis. This suggests that though SPINK1 may not be a 
‘driver’ oncogene in breast cancer, its high expression critically influences key processes 
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in cancer progression including cell survival, drug response and cell invasion, ultimately 
leading to poor clinical outcome. Its association with ER positive tumors makes SPINK1 



























SPINK1, a secreted protein, is found to be highly expressed in tumors as compared to 
normal tissues, and is implicated in poor patient prognosis across multiple cancers 
including prostate, bladder, ovary, liver, pancreas and colon (62-65, 79). We have shown 
in previous chapters that SPINK1 expression is also associated with poorer prognosis in 
estrogen receptor positive breast cancers and that exogenously applied recombinant 
SPINK1 enhances cell invasion in vitro. Moreover, high expression of SPINK1 induced 
resistance to various chemotherapeutic drugs in breast cancer cells. In addition, we 
observed that in some cell lines including MDA-MB-231, NIH-3T3 and in invasive 
primary breast tumors, SPINK1 accumulated in the nucleus. Most cell lines tested 
showed rapid cytoplasmic uptake of exogenous SPINK1, suggesting an intracellular 
function for SPINK1. However, despite the significant roles of SPINK1 in cancer 
progression, very little is known about how SPINK1 brings about such effects.  
Previously, because of its size and structural similarity to epidermal growth factor 
(EGF), SPINK1 has been hypothesized to bind to EGFR (77, 80). Ozaki et al. used 
quartz-crystal microbalance to show that recombinant SPINK1 binds to EGFR with half 
the affinity of EGF. Upon addition of SPINK1 to recombinant pancreatic cancer cells, 
EGFR and its downstream target STAT3 were phosphorylated, eventually leading to 
increased proliferation of the cells (77). EGFR-specific antibodies were also shown to 
abrogate the ability of SPINK1 to induce migration in pancreatic cells(80).  
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To investigate the molecular mechanism involved in SPINK1 internalization that 
we observed and its relevance to oncogenic properties conferred on cancer cells, we 
studied the relationship between EGFR expression and activation following SPINK1 
treatment of various cell lines. Interestingly, our investigations provide conclusive 
evidence that SPINK1 does not signal via the EGF receptor to mediate the known 
oncogenic effects of SPINK1.  
To date, the only known physiological function of SPINK1 is serine protease 
inhibition. Although serine proteases have long been established to promote tumor cell 
invasion by facilitating digestion of extracellular matrixes, serpins have recently been 
found to also promote tumor progression (81). An inactivating mutation of SPINK1’s 
trypsin binding site was found to null the ability of SPINK1 to induce invasion in colon 
cancer cells (64). As opposed to their findings in colon cancer cells, we found that 
recombinant SPINK1 with the same point mutation (K18Y) was still able to induce 
invasion of breast cancer cells as well as colon cancer cell line HCT116. However, 
SPINK1-K18Y, unlike wildtype SPINK1, was unable to rescue cells from apoptosis, 
indicating that the serine protease activity of SPINK1 is required for its drug-resistance 
effects. This suggests that SPINK1 induces cellular invasion and protects cells from 
apoptosis through two distinct pathways.  
To further study the molecular mechanisms of SPINK1, we treated MDA-MB-
231 cells with exogenous SPINK1 across different timepoints and analyzed changes in 
gene expression profiles upon SPINK1 treatment. We confirmed apoptosis and invasion 
to be the two main phenotypes induced by SPINK1. Through this analysis, we also 
identified granzyme B and ATM signaling pathways to be the most strongly regulated by 
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SPINK1 treatment. We validated these findings by western blot, and conclude that 
SPINK1 promotes cell survival by altering the levels of key apoptotic regulators Bcl-2 




Reduction of endogenous EGFR levels does not reduce invasive effect of SPINK1. 
It had been postulated that SPINK1 may interact with EGFR to induce oncogenic effects 
in colon and pancreatic cancer cell lines (64, 77). We attenuated EGFR transcript levels 
by siRNA in EGFR-positive breast cancer cell line MDA-MB-231. As shown in figure 
4.4A, there was a 90% reduction in EGFR levels in MDA-MB-231 cells upon siRNA 
knockdown after 2 days. These cells were then used in invasion assays with 
SF9spink1CM or SF9vecCM as a control. Despite the loss of EGFR protein, the cells 
were 3 times more invasive in the presence of SPINK1 as compared to the SF9vecCM 
control (Figure 4.1A). We then expanded this assay to include a panel of 5 breast cell 
lines expressing varying levels of EGFR, and showed that SPINK1 was able to induce 
cellular invasion regardless of endogenous EGFR levels in all the cell lines tested (Figure 




Figure 4.1: Effect of varying EGFR levels on SPINK1-triggered cellular invasion. (A) 
Invasion of MDA-MB-231 cells was measured following treatment of different CMs in 
presence or absence of EGFR expression. The number of cells invaded is plotted as a 
ratio to SF9vecCM. The inset shows the western blot following siRNA mediated EGFR 
knockdown (B) Invasion of a panel of breast cell lines upon exposure to exogenous 
SF9spink1CM. The number of cells invaded in each cell line is plotted as a percentage of 




Presence of EGFR is not required for SPINK1 internalization. 
We previously observed the localization of externally added SPINK1 into the nuclei of 
MDA-MB-231 cells after 24 hours (chapter 3, Figure 3.12D). In order to investigate 
whether this nuclear entry of SPINK1 is dependent on EGFR levels, we knocked down 
EGFR in MDA-MB-231 cells and observed the localization of exogenous SPINK1. We 
observed that SPINK1 localizes into the nucleus in both the scram-kd and EGFR-kd cells 
(Figure 4.2A). Further, we treated EGFR-null 32D cells with recombinant SPINK1 to 
determine if uptake of SPINK1 was affected in these cells. As shown in figure 4.2B, 
SPINK1 was also internalized in these cells. Based on this data, we conclude that neither 




Figure 4.2: Effect of varying EGFR levels on SPINK1 internalization. (A) Nuclear 
localization of SPINK1 in MDA-MB-231 cells-SPINK1 from SF9spink1CM was added 
to MDA-MB-231 cells and incubated at 37oC for 24hours in MDA-MB-231 cells treated 
with scrambled (scram-kd) or EGFR siRNA (EGFR-kd). Cells not treated with SPINK1 
were used as a control. (B) Internalization of SPINK1 into EGFR-null 32D cell line 





EGFR is not activated by SPINK1 in breast cancer cells. 
Although siRNA knockdown of EGFR was effective in MDA-MB-231 breast cancer 
cells, the loss of EGFR was not complete. We thus decided to do an activity assay on 
EGFR in MDA-MB-231 cells upon SPINK1 treatment. We treated MDA-MB-231 cells 
with EGF or SPINK1 for 10minutes, and observed the phosphorylation status of EGFR in 
the cells. EGFR was activated and phosphorylated by EGF treatment, but not with 
SPINK1, thus confirming that SPINK1 does not activate EGFR in MDA-MB-231 (Figure 
4.4).  
 
Figure 4.3: Phosphorylation status of MDA-MB-231 cells upon EGF and SPINK1 
stimulation. MDA-MB-231 cells were exposed to EGF (10ng/ml) or SF9spink1CM for 
10minutes, and the phosphorylation of EGFR was studied using immunoblotting. 
 
SPINK1 does not trigger the same EGFR pathway as EGF.  
Given that the 32D cells’ dependence on IL-3 for proliferation can be substituted with the 
EGF-EGFR signaling pathway, we hypothesized that if SPINK1 binds to EGFR like EGF, 
it would lead to phosphorylation of EGFR, trigger the same pathway and enable EGFR-
overexpressing 32D cells (32D-EGFR) to proliferate in the absence of IL-3 and EGF. For 
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this, 32D-vec and 32D-EGFR cells were treated with media supplemented either with 
EGF (10ng/ml) as a positive control, VecCM and SF9vecCM as negative controls, or 
SPINK1 (SH5CM and SF9spink1CM). The experiments were carried out in the absence 
of IL-3. As shown in figure 4.4, SPINK1 was unable to replace EGF to stimulate 
proliferation in 32D-EGFR cells, thus confirming that SPINK1 does not trigger the 




Figure 4.4: Effects of SPINK1 and EGF on 32D-EGFR cells in the absence of IL-3.  
32D-vec and 32D-EGFR cells were grown without IL-3 for 48hours, and then 
supplemented with EGF (10ng/ml), VecCM, SH5CM, SF9vecCM or SF9spink1CM (day 
1) for 72 hours (day 3). Cell proliferation was measured using WST-1 and cell number at 




SPINK1 and EGFR expression in breast cancer patients. 
We posited that if SPINK1 binds and functions through EGFR, the prognostic ability of 
SPINK1 should be dependent on EGFR levels, and the expression of SPINK1 should 
correlate with that of EGFR in tumors. We tested this relationship across five 
independent cohorts of breast cancers, as well as by immunohistochemical (IHC) staining 
of SPINK1. We found that the prognostic value of SPINK1 in breast cancer is the same 
in patients with low EGFR (Figure 4.5, top panel) and patients expressing high levels of 
EGFR (Figure 4.5, middle panel) in all cohorts studied. Furthermore, at the protein level, 
immunohistochemical staining of SPINK1 in a panel of 60 breast tumors show that there 
was no association of SPINK1 expression with EGFR protein levels (Figure 4.6B), as 
opposed to what would be expected if the two proteins were interacting closely (Figure 
4.6A). Taken together, we show definitive evidence that SPINK1 does not bind to EGFR, 




Figure 4.5: Analysis of association between SPINK1 expression and prognosis in 
patients with high EGFR and low EGFR expression. Meta-analysis of cohorts from Wang 
(GSE2034) (58), Van (82), Uppsala (GSE3494) (55), Chin (69) and Oxf (GSE6532) (56), 
divided into cases with low EGFR expression (top panel), cases with high EGFR 
expression (middle panel) and all combined (bottom panel). All cohorts display an 
association of SPINK1 expression with poor outcome, which is independent of EGFR 




Figure 4.6: Immunohistochemical staining of EGFR and SPINK1 in breast cancer tissue 
arrays. (A) Example of SPINK1 staining in a breast tumor core, taken at 400X 
magnification. (B) The expected correlation of SPINK1 and EGFR expression if EGFR is 
a receptor to SPINK1. (C) The observed protein levels of SPINK1 and EGFR across 60 
breast tumors. EGFR scoring from 0-3 is available commercially, while SPINK1 staining 
is scored independently on a scale of 0-3.   
 
Induction of invasion by SPINK1 is independent of trypsin inhibition. 
Given that SPINK1 is a trypsin inhibitor, it is possible that SPINK1 promotes cellular 
invasion through the inhibition of trypsin or other serine proteases (81). To investigate 
this possibility, mutant SPINK1 (K18Y) was made with a point mutation at the trypsin 
binding site, disrupting the ability of SPINK1 to bind and inhibit trypsin (64). We added 
K18YCM to MDA-MB-231 cells, and found that K18YCM was still able to induce 
cellular invasion like wild-type SPINK1, suggesting that the induction of cell motility in 




Figure 4.7: Effect of mutant SPINK1. (A) Western blot showing expression of K18Y 
mutant SPINK1. (B) Invasion of MDA-MB-231 treated with wildtype SPINK1 and 
mutant SPINK1. Boyden chamber assays were set up with either wildtype-SPINK1CM or 
mutant-SPINK1CM at the bottom of the chambers, produced from the baculoviral insect 
system. Number of cells invaded was measure 24 hours after assay setup.  
 
Trypsin binding site is required for SPINK1-induced drug resistance. 
With the same SPINK1 mutant, drug resistance experiments were carried out with 
wildtype SPINK1-CM as a positive control. Although SPINK1-CM protected breast 
cancer cells from drug-induced apoptosis, SPINK1-K18Y-CM was unable to do so 
(Figure 4.8). This suggests that trypsin inhibition, or at least serine protease binding, is 




Figure 4.8: Induction of cell resistance to chemically-induced apoptosis. Parental MCF-7 
cells were pretreated with vecCM (white bars), wildtype SPINK1CM (black bars) or 
mutant K18YCM and then exposed to various doses of (A) 5FU and (B) SAHA for 24 
hours. Apoptosis was measured via activated PARP (left panels) and activated caspase-3 
(right panels) levels. (* p<0.005; ** p<0.05; *** p<1E^-05) 
 
SPINK1 mainly regulates cellular apoptosis and invasion. 
In a discovery approach to find out what SPINK1 does in a cancer cell, we treated MDA-
MB-231 breast cancer cells with SPINK1 and observed the expression changes at 3 
timepoints across a span of 24hours (2hour, 12hour, 24hours after treatment). MDA-MB-
231 cells treated with vector conditioned media were used as controls for each timepoint, 
and triplicates were carried out per sample. The samples were probed and hybridized onto 
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Affymetrix U133 plus 2.0 array chips. After normalization, genes that were at least 1.5-
fold increased or decreased as compared to the control across all timepoints were 
extracted using Partek Genomics Suite and entered into Ingenuity Pathway Analysis 
(IPA). From the GO analysis, the top 2 functions regulated were “cellular death” and 
“cellular movement”, confirming our previous observations of SPINK1 treatment (Table 
4.1). This also suggests that we did not miss out on any other function of SPINK1 in our 
phenotypic analyses.  
 
SPINK1 induces resistance to apoptosis through regulation of main apoptotic 
players. 
To understand the signaling involved in SPINK1’s induction of invasion and prevention 
of apoptosis in cancer cells, we analyzed our microarray data in more detail. A pathway 
analysis by IPA revealed “granzyme B signaling” and “ATM signaling” as the top 2 
pathways that were altered with SPINK1 treatment (Table 4.2). A quick look at the genes 
regulated in these pathways and we found that the apoptotic-inducer caspase-3 was 
downregulated very early within 2 hours of SPINK1 treatment. Conversely, apoptosis-
inhibitor Bcl-2 was highly upregulated across all timepoints of SPINK1 treatment. In 
order to further validate these findings at a protein level, MCF-7 cells were treated with 
SPINK1 for 2 hours before harvesting the cells for western blot analysis. Stable clones 
overexpressing SPINK1 at varying levels were also analyzed with cells transfected with 
an empty vector as control. We found that although caspase-3 was downregulated at the 
RNA level, protein changes were not significant with SPINK1 treatment (Figure 4.9A). 
Endogenous caspase-3 levels were, however, largely decreased in the stable clones 
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overexpressing SPINK1, in a dose-dependent manner (Figure 4.9B). On the other hand, 
apoptosis-inhibitor Bcl-2 levels were consistently upregulated with increasing levels of 
SPINK1 in the SPINK1 overexpressing stable clones, and also increased upon SPINK1 
pre-treatment to breast cancer cells, regardless of the drug treatment. Other apoptotic 
regulators such as BID and caspase-8 were not regulated with SPINK1 treatment nor 
overexpression (Figure 4.9). This suggests that SPINK1 protects cells from apoptosis by 
the upregulation of Bcl-2 in breast cancer cells, and further downregulates caspase-3 
levels with extended exposure to SPINK1. This supports our previous apoptosis data in 
Chapter 3 (Figure 3.13), where we observed that the protective effects of SPINK1 in 
SPINK-overexpressing cells were much more significant than in cells that were pre-























Table 4.1 (cont.): 
 
Genes that are regulated at least 1.5 fold upon SPINK1 treatment across all timepoints as 
selected by Partek Genomics Suite were entered into IPA. Top 10 GO predictions of 
these regulated genes.  
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Table 4.2: Pathway analysis from Ingenuity Pathway Analysis. 
 




Figure 4.9: Protein levels of apoptotic players upon exposure to SPINK1. Protein levels 
of main apoptotic regulators were measured via western blot (A) 2 hours after SPINK1-
CM was added to MCF-7 cells and (B) in MCF-7 cells that overexpress SPINK1 at 
varying levels, with empty vector overexpression as a control.  
 
Discussion 
SPINK1 is a prognostic biomarker in multiple cancer types, including ovarian, liver, 
prostate, pancreatic and bladder cancer (62-65). Although it has been well established 
that high expression of SPINK1 is associated with poor survival in cancer, its mechanism 
of action has not been clearly established.  
There has also been much postulation that SPINK1 binds and activates EGFR due 
to its sequence and structural similarity to EGF. Marchbank et al. showed that migration 
in human pancreatic cancer cells by SPINK1 could be negated completely with 
antibodies against EGFR (80). A recent publication by Ozaki et al. further suggested that 
SPINK1 binds weakly to EGFR, phosphorylates EGFR and leads to enhanced 
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proliferation of pancreatic cancer cells through the EGFR pathway (77). On the other 
hand, two other independent groups used radioactive labeling to show that although there 
is a SPINK1 receptor, binding of SPINK1 to the receptor could not be competitively 
blocked by EGF. In the same study, Niinobu et al. also showed that SPINK1 and EGF 
induced growth in 3T3 cells in a synergistic rather than additive manner, suggesting two 
independent pathways stimulated by the two proteins (83, 84).  
Our initial observations in breast cancer cells suggested that SPINK1 induces 
invasion in breast cancer cells, and can be rapidly internalized by cells to localize to the 
nucleus. Since we observed a similar nuclear staining in primary tumors, we investigated 
if EGFR was responsible for receptor-mediated SPINK1 endocytosis. First, we performed 
siRNA-mediated depletion of EGFR protein in MDA-MB-231 cells and showed that the 
cells remained responsive to SPINK1 as demonstrated by increased invasion of the cells. 
Further, this observation was consistent in multiple breast cell lines expressing different 
levels of EGFR. This is further supported by the detection of EGFR phosphorylation 
upon treatment of EGF, but not SPINK1. We then used EGFR-null 32D cells, which are 
completely dependent on IL-3 for survival. Previously, McCloskey et al. had shown 
transfection of recombinant EGFR in 32D cells and treatment with EGF can lead to cell 
proliferation in the absence of IL-3 (85). We hypothesized that if SPINK1 mediated its 
responses via EGFR, it may be able to functionally replace EGF as a ligand in this assay. 
With the use of this 32D-EGFR system, we show that only EGF is able to stimulate 
EGFR in a manner which can result in the cells proliferating in the absence of IL-3, while 
SPINK1 is unable to do so. Moreover, the parental EGFR-null 32D cells were able to 
internalize SPINK1, suggesting that the entry of SPINK1 did not require the presence of 
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EGFR. Together, these data suggest that SPINK1 may not signal via EGFR to mediate its 
invasive functions in breast cancer.  
Both EGFR and SPINK1 are associated with poor outcome in breast cancer (86), 
and if they form a functional ligand-receptor complex in tumor tissues, they would most 
likely be co-expressed in the same tumors. We studied the correlation of SPINK1 and 
EGFR RNA across multiple cohorts, as well as studied their protein localization in 60 
patient samples. However, we did not observe any such correlation or co-expression of 
the two genes. Together, these data suggest that EGFR may not be essential for SPINK1-
mediated pathways in breast cancer and further investigation to identify such novel 
mechanisms is required. 
Given that serine protease inhibition is the sole function of SPINK1 documented, 
we mutated SPINK1 at its trypsin binding site to investigate the possibility of SPINK1 
accelerating tumor progression through regulating serine protease activity. Contrary to 
findings by Gouyer et al.(64), the trypsin binding ability of SPINK1 was not essential for 
SPINK1 to induce breast cancer invasion. Instead, we discovered that this activity was 
critical in the ability of SPINK1 to induce drug-induced apoptosis. Lu et al.(87) 
suggested that SPINK1 inhibits only serine protease-dependent apoptosis (SPDCA) 
owing to its protease inhibitor function but has no role to play in caspase-dependent 
apoptosis (CDCA) in human hepatoma cells. Since intact protease inhibitor activity was 
required for the protection, we suggest that that SPINK1 probably interferes in both the 
CDCA and SPDCA pathways in breast cancer cells resulting efficient chemoresistance. 
Conceivably, attenuation of SPINK1 expression in breast cancer may accentuate the 
efficacy of anticancer therapies (88-90). Another protease inhibitor, plasminogen 
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activator inhibitor -1 (PAI-1), was also recently found to protect cells from FasL-
mediated apoptosis through its serine protease activity (81). This bifurcation of SPINK1 
activity could have important implications in drug therapy, by allowing specific targeting 
of SPINK1 anti-apoptotic activity without affecting the physiological trypsin inhibitory 
functions of SPINK1, thus minimizing any possible side effects of the therapy.  
To investigate the signaling pathway of SPINK1, microarray was done on breast 
cancer cells that have been treated with recombinant SPINK1. We identified cell death 
and cell motility signaling pathways to be the most strongly regulated upon SPINK1 
treatment. Through western blot, we confirmed that SPINK1 upregulates Bcl-2 in both 
autocrine and paracrine manners, and downregulates caspase-3 protein levels in breast 
cancer cells upon extended exposure to SPINK1. We thus conclude that SPINK1 alters 
transcription and translation of key apoptotic regulators to induce a protective effect on 
cancer cells.  
From the microarray data, we had hints that SPINK1 may interact with granzyme 
B. Interestingly, granzyme B is a cell surface protein that functions as a serine protease. 
SPINK1, being a serine protease inhibitor, could possibly bind to and inhibit granzyme B. 
A recent publication by Tsuzuki et al. (91) showed that granzyme A, which is structurally 
similar to granzyme B, physically interacts with the rat homolog of SPINK1. Granzyme 
B expression has been shown to lower nodal metastasis and is positively correlated with 
good prognosis in breast cancer (92, 93). Further, granzyme B-mediated apoptosis 
proceeds through a bcl-2 inhibitable pathway (94). With data that suggests that the anti-
apoptotic functions of SPINK1 are through its serine protease inhibitory effects, we 
hypothesize that SPINK1 could possibly bind to granzyme B in human breast cancer cells, 
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leading to the internalization and possibly inhibition of downstream granzyme B 
apoptotic signaling as well as various metastasis and prognosis effects as observed 
previously. This interaction, however, remains to be confirmed with further experiments.  
 By mutating the trypsin binding site of SPINK1, we discovered that there is a 
bifurcation of pathways between SPINK1-mediated drug resistance and SPINK1-
mediated invasion. Following this interesting observation that mutant SPINK1 can still 
enhance invasion but not stimulate drug resistance in breast cancer cells, more work 
needs to be done to investigate the dual function of SPINK1. In addition to the 
microarray with SPINK1 treatment, a similar microarray should be done on cells that are 
treated with mutant SPINK1-K18YCM. A comparison between the two gene signatures 
could reveal specific pathways unique to each of the functions of SPINK1.   
In order to fully understand how secreted SPINK1 regulates expression of 
apoptotic-family genes as well as control cell motility, the identification of the true 
SPINK1 receptor would be critical. This could be done by the treatment of tagged 
recombinant SPINK1 to cells, followed by cross-linking, pull-down and mass 
spectrometry. However, only unbound SPINK1 can be immunoprecipitated, while 
attempts at pulling down SPINK1 and its interacting partner were futile (data not shown). 
Given the small size of SPINK1 and the predicted relatively large size of the putative 
receptor (83), SPINK1 could be completely engulfed by the receptor upon binding, 
making it almost impossible to immunoprecipitate the receptor-ligand complex. The C-
terminal 6XHis-tag of SPINK1 was not useful either, as it gets coiled right into the 
middle of the ball-like SPINK1 upon tertiary folding (data not shown). An alternative to 
this would be to use SPINK1 tagged at the N-terminus after the secretory signal for 
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immunoprecipitating the receptor-ligand complex. If the SPINK1 receptor is identified, 
elucidation of SPINK1 signaling in cancer cells would be greatly facilitated, and would 







Chapter 5: Genomic Discovery of Novel Tumor Suppressor Genes in Breast Cancer 
from a Single Cell Line 
 
Introduction 
Cancer cells dysregulate of two main classes of genes: activation of oncogenes and 
silencing of tumor suppressor genes. Tumor suppressor genes (TSGs) function primarily 
to inhibit cell growth, invasiveness, or genomic stability and their inactivation by 
mutation, deletion, or epigenetic silencing contributes to the malignant state. In the past, 
the discovery of tumor suppressor genes has been often conducted by mapping common 
regions in cancers with loss of heterozygosity (LOH) followed by sequencing candidate 
genes within those genomic regions of minimal overlap for inactivating mutations or 
deletions.  Both the tumor suppressors cyclin-dependent kinase inhibitor 2A (CDKN2A) 
and the retinoblastoma 1 (Rb1) exhibit LOH in many cancers with the remaining allele 
either subject to deletion, inactivation by stop codon substitution, or epigenetic silencing. 
LOH mapping is an imprecise and burdensome process: many tumors and their matched 
normal DNA are required, yet the gene resolution is poor, making this approach 
impractical.    
We developed a highly efficient approach to identifying novel tumor suppressor 
genes using comprehensive genomic technologies and judicious use of genomic 
databases. We reasoned that by examining regions of the genome where there is a 
decrease in copy number coupled with reduction to homozygosity (RTH) and silencing of 
transcription, novel tumor suppressor genes can be identified. Here, we used the well 
characterized breast cancer cell line, MCF-7, as a model. With a largely tetraploid 
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chromosomal backbone, we hypothesized that important tumor suppressor genes would 
be silenced in MCF-7 by multiple mechanisms to ensure complete silencing. Thus, by 
using SNP information of MCF-7, we identified regions that display RTH as well as a 
decrease in copy number. Potential tumor suppressor genes located within these regions 
were then assessed using multiple methods to ensure their lack of transcription, and 
rigorously tested for their association with distant metastasis-free survival (DMFS) in a 
cohort of over 1200 breast tumors. From the resultant list of candidate tumor suppressor 
genes, we discovered that they form a closely-knit network of tumor suppressor genes, 




Integrative genomics analysis reveals 12 potential tumor suppressor genes 
associated with patient prognosis. 
The MCF-7 cell line is pseudo-tetraploid, thus there can be regions in MCF-7 that have a 
decrease in copy number but still be heterozygous (e.g. AABB with a deletion resulting 
in AAB). We hypothesized that in such pseudo-tetraploid cells, multiple silencing 
mechanisms may be required to result in the complete silencing of key tumor suppressor 
genes. Hence, we searched for genomic regions in the MCF7 cell line genome using 
stringent criteria for likely gene silencing: regions that have a copy number decrease and 
display reduction to homozygosity (RTH) at the nucleotide level. By looking at SNP data 
generated from Illumina 1 million SNP array and analyzed with OverUnder algorithm 
(95), genomic regions displaying reduction to homozygosity that also had a decrease in 
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copy number (aCGH CN<3) were identified along the MCF-7 genome. Well 
characterized tumor suppressor genes such as FHIT, p53 and p16 were also picked up at 
this point. We had previously published the distant pair-end tag whole genome sequence 
(gPET) data for MCF-7 (96) which provides the detailed genomic structure for the cell 
line to about 200X clonal coverage. This structural information, to about 100-250 base 
pair resolution, includes copy number and genomic rearrangements. Genes located in 
those regions of combined RTH and copy number reduction detected by the arrays had 
their copy number and structural configuration confirmed by analysis of this gPET data 
on the MCF-7 cell line (gPET CN<1.75).  We had also previously performed deep RNA-
seq on the same MCF-7 cell line (96, 97) and used this dataset to further filter the RTH 
list for only genes that were not transcribed as assessed by RNA-seq. A very stringent 
cutoff of <1.0 tags per million per kb of gene length (TpMpKB) was used to filter away 
genes that were expressed in MCF-7 either under normal culture conditions or 
stimulation with estradiol (Table 5.1, EtOH and E2 respectively). Of 292 genes that 
resided in regions that have both RTH and a decrease in copy number (Figure 5.1), 275 
(94.2%) were confirmed to have a copy number decrease with gPET data. Of these, 109 
(39.6%) had no detectable expression throughout the gene using RNA-seq, while 1 gene 
had no detectable expression in half of the gene (Figure 5.2, Table 5.1). The addition of 
RNA-seq as a filter also removed potential and known tumor suppressor genes that are 
inactivated through mutations, because such mutated tumor suppressor genes are usually 
still expressed. An example of such a tumor suppressor gene that is filtered away is p53, 
which is often expressed in tumors in a mutated and thus inactivated form. 68 genes of 
the resultant 110 candidate tumor suppressor genes which had microarray expression 
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information were then assessed for their association with DMFS in publicly available 
breast cancer datasets. Cox proportion hazards regression was performed on each 
candidate gene across 6 independent breast cancer cohorts to investigate its association 
with DMFS. A combined meta-analysis was then performed on all 6 cohorts consisting of 
a total of 1227 cases. From this analysis, 12 (17.6%, or 4.1% of total) candidate tumor 
suppressor genes were identified to be significantly associated with prognosis (p-
value<0.05; Table 5.1, Figure 5.3). 
 
Table 5.1: List of the 12 candidate tumor suppressor genes 
 
*RPL29 has RNA-seq tag reads only on its 3’UTR and part of the first exon. Tag counts 






Figure 5.1: Example of selected genomic regions with both RTH and CN decrease. Copy 
numbers estimated by SNPs are plotted against chromosomal location along each 
chromosome. Each blue dot represents one SNP. Purple regions indicate homozygous 
regions; Red boxes indicate regions that are picked for the search of tumor suppressor 
genes in chromosome 6 (top) and 9 (bottom). (Note: Analyses were performed together 
with Dr Jianjun Liu’s team, in particular Astrid Irwanto, Human Genetics Department, 





Figure 5.2: Screenshots from UCSC browser displaying RNA-seq readouts. Each blue 
tag represents one RNA-seq read in that position. Many tags stacked up vertically 
indicate multiple reads in that location, implying high expression of that gene in MCF-7. 
(A) Example of a gene highly expressed in MCF-7 as shown by RNA-seq. (B) Example 







Figure 5.3: Example of a candidate tumor suppressor gene that had significant 
association of expression with good survival. (A) Survival curves of one of the candidate 
85 
 
tumor suppressor genes, SEMA6D across all 6 breast cancer cohorts analyzed. (B) Meta-
analysis of SEMA6D. Overall hazard ratio of 1.728; p-value=4.29 E-08; confidence 
interval [1.421, 2.101]) 
 
Candidate tumor suppressor genes have similar expression patterns across tissue 
types. 
Although these 12 candidate tumor suppressor genes were identified using breast cancer 
as a model, we assessed whether these could also be associated with suppression of tumor 
progression in other tissue types. Expression information of each gene in normal and 
cancer tissues was obtained from the Oncomine database. Interestingly, our search 
revealed that all 12 genes are downregulated in many epithelial tumors as compared to 
normal tissue (Table 5.2). This suggests that these genes are not only important in 
blocking breast cancer progression, but probably function as general tumor suppressor 
genes across multiple tissue types.  
 
 
Table 5.2: Oncomine information of expression of all 12 candidate tumor suppressor 
genes across multiple tissue types. Cohorts in which candidate genes were significantly 
upregulated in cancer tissues as compared to normal tissues were colored in red, while 
cohorts in which candidate genes were significantly downregulated in cancer tissues were 
colored green. Intensity of colors indicates the number of cohorts that displayed the same 
trend, with the darkest shade representing the highest number of cohorts. White regions 






Paired-wise association of candidate tumor suppressor genes reveals closed tumor 
suppressor gene network. 
Gene-gene interactions have been well documented in other systems, thus we 
hypothesized that some of the candidate tumor suppressor genes may function together in 
a synergistic manner, associated with a much better prognosis when overexpressed 
together as compared to when either gene is expressed alone. Candidate tumor suppressor 
genes were randomly paired and grouped according to their relative expressions (either 
co-expressed or inversely-expressed) in each of 760 breast cancer patients. DMFS of 
each pair of genes was then assessed in each group. In the group where tumor suppressor 
genes were inversely-expressed, the resultant prognostic value of the pair was either the 
same or even worse than each gene on its own (Table 5.3). However, in the group where 
tumor suppressor gene pairs were both upregulated together, the resultant prognostic 
value of the pair tended to be several times better than either gene alone. This new 
prognostic ability of the pair was compared to that of each individual gene by taking a 
ratio of the smaller p-value of the 2 genes to the new combined p-value. Of the 191 pairs 
analyzed, 31 pairs had at least a ten-fold increase in the prognostic ability of the pair as 
compared to each individual gene alone, with the top pair having more than a thousand-
fold improvement in prognostic value (from p=0.02 to p=1.25E-05). Interestingly, 27 out 
of these 31 tumor suppressor pairs engaged the same gene, SEMA6D (Table 5.3, Table 
5.4), implying that suppression of SEMA6D expression is the major modulator of the 
survival effects of the other 11 candidate tumor suppressorgenes. Thus, we hypothesize 
that all 12 candidate tumor suppressor genes function together as a closely-integrated 




Table 5.3: List of paired candidate tumor suppressor genes with their resultant 
association with DMFS when inversely expressed.  
 
PvPr and hrPr are the combined p-value and the combined hazard ratio of the pair 
respectively; pvOne and pvTwo are the p-values of each individual gene; hrOne and 
hrTwo are the hazard ratios of each individual gene; Pvratio is the fold increase of the 
paired genes p-value (PvPr) as compared to the lower p-value of either gene (pvOne and 
pvTwo). (Note: Analyses were performed by Dr Krishna K Murthy, Computational and 





Table 5.4: List of paired candidate tumor suppressor genes with their resultant 
association with DMFS when co-expressed.  
 
 
PvPr and hrPr are the combined p-value and the combined hazard ratio of the pair 
respectively; pvOne and pvTwo are the p-values of each individual gene; hrOne and 
hrTwo are the hazard ratios of each individual gene; Pvratio is the fold increase of the 
paired genes p-value (PvPr) as compared to the lower p-value of either gene (pvOne and 
pvTwo). (Note: Analyses were performed by Dr Krishna K Murthy, Computational and 




Figure 5.4: Hypothetical integrative network of tumor suppressor genes. 
 
Discussion 
In this study, we sought to identify novel tumor suppressor genes by mining multiple 
genomic datasets of the MCF-7 breast cancer cell line. Using dense SNP arrays, we 
identified almost 300 genes located in genomic regions with decreased copy numbers 
coupled with RTH (reduction to homozygosity). Approximately a third of these genes 
were not transcribed in MCF-7, of which 12 were found to be significantly associated 
with good prognosis in 6 independent breast cancer datasets. Through a conjoint analysis 
of these 12 genes, we found that the candidate tumor suppressor genes form an integrated 








Semaphorins are normally expressed in the brain and nervous system, playing a role in 
the development of the nervous system as well as axon guidance. They are generally 
transmembrane receptors, but are sometimes cleaved and secreted extracellularly. 
Recently, misregulation of semaphorin family members has been documented in multiple 
cancer types. However, there is no clear role of sempahorins in cancer progression, with 
some functioning as tumor suppressor genes while others promote oncogenesis (98-106).  
Interestingly, some semaphorins display dual roles in cancer. One example is semaphorin 
3E (SEMA3E), which blocks angiogenesis and inhibits tumor growth in most cancer 
types, but promotes metastasis of colon and liver cancer (107, 108). This dual role is 
postulated to be a result of different receptors being expressed in the different tissue types, 
resulting in varied signaling responses by the promiscuous binding of SEMA3E.  
Although the semaphorin family has been found to have a close association with 
cancer progression, the role of SEMA6D in cancer is unclear (101, 102, 109). To 
investigate how higher SEMA6D expression results in better breast cancer prognosis, we 
sought to observe phenotypic changes through transient and stable overexpression of 
SEMA6D in breast cancer cell lines that have no endogenous SEMA6D expression. We 
found that although SEMA6D was successfully transfected into the cancer cell lines and 
RNA expression of SEMA6D was high, no protein was made by the cells. Given that the 
cells could have blocked the translation of SEMA6D due to its detrimental effects on 
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cancer cell growth, we went on to do inducible expression of SEMA6D in breast cancer 
cells. Upon induction of SEMA6D, apoptosis was induced in the cells, confirming that 





SEMA6D, the most prominent tumor suppressor gene candidate amongst all 
semaphorins. 
Semephorins and their receptor plexins have been implicated in numerous disease states, 
including the regulation of cellular migration and angiogenesis (102, 109). Semaphorins 
3B and 3F (SEMA3B and SEMA3F) have been identified as potential tumor suppressor 
genes as they localize in regions of the genome that are frequently deleted or reduced to 
homozygosity in cancer (100, 105). Further, SEMA3F has been shown to inhibit tumor 
growth in mice (100). To investigate the difference between SEMA6D and the other 
semaphorins as well as plexins, the same analysis was done on all semaphorins and 
plexins (including copy number, RTH status, expression and association with patient 
prognosis) (Table 6.1). Although SEMA3B and 3F are located in RTH regions that are 
also deleted in MCF7, these genes failed to make the mark as they are still expressed as 
measured at the RNA level. The only semaphorins that were completely silenced were 
SEMA3A, SEMA3D and SEMA6D, of which SEMA3A and 3D were both not associated 
with prognosis. In fact, all the semaphorins and plexins except for SEMA6D were found 
not to be associated with good survival (Table 6.2). Therefore, although other 
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semaphorins have been previously identified to lie within RTH regions that were deleted, 
our screen identified SEMA6D to be the most prominent semaphorin member with its 
strong association with good patient prognosis.  
 

























Expression of SEMA6D in normal breast is lost in breast cancer.   
Genes that are found to be deleted and silenced in cancer tissue are often later discovered 
to be silenced in normal tissue as well. In order to make sure this is not the case of 
SEMA6D, we did a real-time PCR on 5 sets of commercial normal breast RNA, 5 breast 
cancer cell lines and 1 immortalized “normal” breast cell line. Both isoforms of 
SEMA6D (SEMA6D.4 and SEMA6D.6) were expressed in all normal breast samples, but 
expression was either extremely low or not detectable in all breast cancer cell lines 
analyzed (Figure 4). Non-tumorigenic breast cell line MCF10A also did not have 
detectable SEMA6D expression, suggesting that SEMA6D may be switched off early in 
tumorigenesis at the immortalization process of the cell line. 
 We then expanded this analysis to look at the expression of SEMA6D across 
multiple cancer tissues in the oncomine database. Similar to our observation, SEMA6D 
was found to have lower expression in breast cancer tissue as compared to normal breast 
tissue. The same trend was found in many other tissue types, including the colon, prostate, 
liver and kidney (Figure 6.2). Hence, we confirm that SEMA6D is expressed in normal 




Figure 6.1: RT-PCR of SEMA6D in breast cancer cell lines and normal breast. RNA 
expression of SEMA6D was checked in a panel of breast cancer cell lines and 
commercially available normal breast RNA, with primers specific to (A) the longer 




Figure 6.2: Oncomine data of SEMA6D expression in multiple cancer types versus 
corresponding normal tissue.  
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SEMA6D expression is toxic to breast cancer cells 
To observe the phenotypic effects on cancer cell lines upon reintroduction of SEMA6D, 
we made constructs containing both isoforms of SEMA6D (SEMA6D.4 and SEMA6D.6) 
with empty vector as a control. Both transient and stable overexpression of SEMA6D 
revealed huge increases in the SEMA6D RNA expression in the cells, indicating 
successful transfection (Figure 6.3). However, no protein was detectable by western 
blotting of both total cell lysates and the conditioned media of the cells, using both 
SEMA6D-specific antibodies as well as antibodies against C-terminal tags added to the 
constructs (data not shown).   
We hypothesized that SEMA6D protein expression was not attainable despite 
efficient transfections due to possible toxicity of SEMA6D protein to the breast cancer 
cells. To investigate this possibility, SEMA6D vector constructs were digested with 
either EcoRI (SEMA6D.4) or Kpn1 (SEMA6D.6) that cleaves SEMA6D without 
cleaving the rest of the vector. Vector constructs were also digested with Not1 that is 
located in the multiple cloning site as a control. Digested constructs were then transfected 
into MCF-7 cells with intact constructs as a control. Transfected cells were cultured in 
the presence of G418 selection media, and the number of resistant colonies formed was 
counted after 2 weeks (Figure 6.4). Cells transfected with SEMA6D inactivated by 
cleavage formed significantly more colonies as compared to cells transfected with the 
intact SEMA6D construct, supporting the hypothesis that SEMA6D expression is indeed 
toxic to the cells.  
 In order to further confirm this observation, an inducible system was set up with 
SEMA6D in a bidirectional vector expressing GFP concurrently. In this MCF7-Tet-
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inducible system, cells that were transfected with SEMA6D/GFP were first selected with 
hygromycin, before expression of SEMA6D/GFP was induced with the addition of 
doxycycline to the growth media. Upon induction, GFP-positive vector cells appeared 
healthy and viable, whereas GFP-positive SEMA6D cells showed signs of cellular stress. 
This was further analyzed quantitatively with flow cytometry on the same population of 
cells. Strikingly, a 30.1% apoptotic population in vector/GFP+ cells increased 
dramatically to 77.2% in SEMA6D/GFP+ expressing cells (Figure 6.5).  Taken together, 
these data suggest that SEMA6D has potent tumor suppressing function and that loss of 
SEMA6D expression by genetic or epigenetic means is not only common in breast 







Figure 6.3: RT-PCR of SEMA6D in overexpressed cell lines. SEMA6D overexpression 
was checked in stably-transfected MCF-7 cells using primers specific to (A) the longer 






Figure 6.4: Number of colonies formed upon transfection of intact and digested 
SEMA6D. MCF-7 cells were transfected with vector constructs expressing intact 
SEMA6D, or with vector constructs that had the SEMA6D fraction cleaved with 
restriction enzyme EcoRI. Transfected cells were selected with G418 and the number of 




Figure 6.5: Flow Cytometry analysis of MCF7 cells induced with SEMA6D expression. 
MCF7-tet cells were transfected with SEMA6D-GFP or empty vector as controls. 
Transfected cells were selected with hygromycin, and induced with doxocycline. 
Apoptotic population of GFP-positive cells was analyzed by flow Cytometry with 
propidium iodide staining. 
 
Discussion 
Vertebrate semaphorins are classified into 5 main classes, classes 3-7 (i.e. 
SEMA3A belongs to class 3 semaphorins and SEMA6D belongs to class 6). Class 3 
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semaphorins, which are the most well studied, are the only semaphorins that are secreted. 
Class 4-7 semaphorins are transmembrane receptors that are distinguished by their 
structural elements and amino acid similarity – for example, class 5 semaphorins have 
thrombospondin repeats and class 7 semaphorins have a glycophosphatidylinositol (GPI) 
anchors. Semaphorins are normally expressed in the brain and nervous system, playing a 
role in the development of the nervous system as well as axon guidance. Recently, 
misregulation of semaphorin family members has also been documented in multiple 
cancer types. However, there is no clear role of sempahorins in cancer progression, with 
some functioning as tumor suppressor genes while others promote oncogenesis (98-106).  
Interestingly, some semaphorins display dual roles in cancer. One example is SEMA3E, 
which blocks angiogenesis and inhibits tumor growth, but promotes metastasis of colon 
and liver cancer (107, 108). This dual role is postulated to be a result of different 
receptors being expressed in the different tissue types, resulting in varied signaling 
responses of SEMA3E. The specific role of SEMA6D in cancer, however, has not been 
extensively studied (100, 101, 108). Though a few semaphorins and their plexin receptors 
were deleted along with SEMA6D in MCF-7, our analysis of all components of the 
semaphorin-plexin family showed that none of them besides SEMA6D were significantly 
associated with prognosis in the breast cancer cohorts studied. This suggests that 
SEMA6D is the most prominent tumor suppressor gene within the semaphorin family.  
Therefore this comprehensive analysis of genomic and transcriptome signatures uncovers 
12 putative tumor suppressor genes and identifies SEMA6D as perhaps the most 
important of the lot in a common cancer (101, 102, 109). 
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Of the 12 putative TSGs identified herein, 4 showed no evidence of expression 
(TpMpKB<2) by RNA-seq in 4 primary breast cancers: SEMA6D, LRRC2, CACNA2D3 
and TSP50 (Table 6.3). Besides SEMA6D, all 3 other putative TSGs lie within the 3p21 
region that is well described to be homozygous in many cancers and thus possibly packed 
with TSGs. LRRC2 is a protein that contains seven leucine-rich repeats. Its closest 
relative is the Ras Suppressor Protein 1 (RSU1), which is able to suppress v-ras induced 
transformation in NIH3T3 fibroblasts, suggesting a possible role of LRRC2 in regulating 
tumorigenesis (Kiss 2002, Cutler 1992). The expression of CACNA2D3 which encodes 
for a member of the voltage-dependent calcium channel complex alpha-2/delta subunit 
has been positively associated with gastric cancer patient survival, and the exogenous 
expression of CACNA2D3 has been shown to strongly inhibit cell growth and adhesion 
of gastric cancer cells, while upregulating cell cycle regulators p21 and p27 (Wanajo 
2008). TSP50, a testes-specific protease, has a less certain role in breast cancer: although 
our analyses show undetectable expression of TSP50 in MCF-7 and 4 independent 
primary breast tumors, another group pointed out that TSP50 is hypomethylated and 
abnormally reactivated in many breast cancer biopsies tested. Further, they showed with 
luciferase assays that p53 overexpression reduces TSP50 promoter activity in a range of 
cell lines, and that TSP50 expression is much higher in cell lines that express mutated 
p53. However, direct interaction between p53 and the TSP50 promoter could not be 
recapitulated with EMSA (Yuan 1999, Xu 2001).  Therefore in all 4 cases, there is 
already experimental plausibility that they are proteins involved in negative tumor growth. 
That their suppression frequently occurs in combination, especially with SEMA6D, to 
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affect clinical outcome in breast cancer, suggests some form of restricted cooperativity 
amongst tumor suppressor elements.    
SEMA6D is normally expressed in normal breast, but is silenced in breast cancer 
cells. This could possibly occur through deletions or structural rearrangements between 
chromosome 15 and other chromosomes, leading to a decrease in copy number of 
SEMA6D. Reintroduction of SEMA6D into the breast cancer cells was only successful at 
the RNA level, but no protein production could be induced. This is not uncommon in the 
overexpression of toxic proteins in cells. We suspect that the cancer cells could have 
developed silencing mechanisms to prevent the induction of SEMA6D due to its 
detrimental effects on the cells, and cells that did synthesize the protein probably did not 
proliferate or died due to the toxic effects of SEMA6D, thus making it undetectable. We 
investigated this possibility by transfecting cells with SEMA6D inactivated by restriction 
digestion, and found that significantly more colonies were formed with inactivated 
SEMA6D as compared to cells that were transfected with the intact SEMA6D construct, 
suggesting that SEMA6D is indeed detrimental to the growth of breast cancer cells. This 
was further confirmed with inducible expression of SEMA6D which resulted in cellular 
apoptosis in breast cancer cells.  
SEMA6D normally binds to the receptor Plexin A1 (PLXNA1) in the heart (110, 
111). PLXNA1 is known to be promiscuous, and binds other ligands including 
semaphorins 3A and 3F, both of which have been shown to reduce tumor growth by the 
inhibition of cell proliferation and angiogenesis (101, 103). Ligand binding to PLXNA1 
activates its intracellular GTPase-activating protein, which in turn promotes intrinsic 
GTPase activity in r-Ras. R-Ras, which is active when bound to GTP, becomes inhibited 
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when GTPase is activated. The increase in GDP-bound r-Ras results in an overall 
inhibition of cellular proliferation as well as the induction of cellular apoptosis (102). If 
SEMA6D also binds and activates PLXNA1 in breast cancer, SEMA6D could possibly 
play a role in cancer inhibition by the blocking of the r-Ras pathways.  
In the past, the search for tumor suppressor genes focused on the analysis of LOH 
in a large number of tumors and assessing the minimal area of overlap of these LOH 
regions.  In this manner, TSGs such as PTEN and SMAD4 (Thiagalingam 1996, Li 1997, 
Steck 1997) were found. This approach, however, proved to be ineffective because the 
mapping approaches had low resolution and the regions of minimal overlap often 
spanned many candidates. The biological and clinical correlative analysis of these 
candidates proved to be impractical in most cases. We present a comprehensive genomic 
strategy relying on integration of detailed heterogeneous datasets for the discovery of 
TSGs. This strategy relied on the principle that genes silenced by genetic means in cancer 
are reasonable TSG candidates (as compared to just the absence of gene expression). In 
the absence of germline DNA, hemizygosity at a gene locus may still be polymorphic. 
Therefore we relied first on a screen for regions of reduction to homozygosity to assess 
segments that have undergone selection for allelic imbalance. We then filtered these 
regions for reduction in copy number by both array and direct sequencing approaches, 
and finally proved that these genes are transcriptionally silent. The biological impact of 
these candidate TSGs were approximated by examining the correlation of gene 
expression with survival in published breast cancer expression array datasets. This 
approach has obvious advantages in that analysis of only one sample is sufficient to 
uncover a trove of candidates with high likelihood of biological effect. Moreover, the 
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knowledge of the genome permits the precise identification of these putative tumor 
suppressors at the gene level. Prospectively, we believe that structured analysis of even a 
small number of primary tumors will uncover a rich network of genes with tumor 
suppressor function that can help explain cancer progression and maintenance.                
 















Chapter 7: Conclusion 
Cancer is a complex disease where multiple genes are involved. Single gene 
mutations are highly unlikely to account fully for tumor initiation and progression – 
crosstalk between multiple driver mutations that result in the dysregulation of critical 
signaling pathways are more likely to be acting in concert to transform a cell to be 
cancerous. Hence, it is critical that a systems biology approach be employed to 
completely characterize the mutational and interactional events occurring in a cancer cell. 
By making use of multiple high throughput technologies, we showed in this thesis report 
that we were able to systematically scan the entire genome for novel potential oncogenes 
and tumor suppressor genes that were major players in the prognosis of patients in the 
clinic. With the in vitro and in vivo validation of these candidates, we show with 
confidence that SPINK1 functions as a promoter of cancer progression, and SEMA6D as 
a key tumor suppressor gene in breast cancer.  
 
Oncogene - SPINK1 
Breast cancer exemplifies both the opportunities and challenges involved in the 
clinical application of gene expression profiling to solid cancers. Examples include the 
70-gene Mammaprint and 21-gene Oncotype Dx classifiers for breast cancer, which were 
developed based on the principle of integrating the effects of multiple oncogenes in 
breast cancer (112, 113). However, there is often very limited overlap between different 
prognostic breast cancer gene lists. Further, the translation of these tests from prognostic 
to therapeutic is challenging. Few of the genes in the prognostic lists were characterized 
to serve as potential therapeutic targets. Motivated by the need to discover new genes that 
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can serve both as a prognostic and therapeutic target, we developed a pipeline to screen 
for novel breast cancer oncogenes that are potentially targetable by small molecules. We 
first tapped on the expression and clinical information of 760 breast tumors from 
independent cohorts. Genes that are associated with poor clinical outcome were selected 
as potential oncogenes. These were further filtered for only potentially targetable genes 
by only focusing on secreted factors and cell surface receptors. The final set of novel 
candidate oncogenes were put through a simple screen of multiple oncogenic phenotypes 
using transient siRNA knockdowns, and we found serine protease inhibitor, SPINK1, to 
be the most prominent candidate oncogene from our screening. By combining 
knockdown, treatment and overexpression experiments, we established that SPINK1 does 
not induce cellular transformation nor stimulates cellular proliferation in breast cancer 
cell lines, but instead induces cellular invasion, promotes metastasis and is an important 
survival factor that also increases the resistance of cells to chemically-induced apoptosis. 
Further investigation of the downstream pathways revealed that SPINK1 regulates drug 
resistance in cancer cells by modulating levels of key apoptotic players Bcl-2 and 
caspase3, a process that is dependent on the trypsin binding site of SPINK1. SPINK1-
mediated invasion, on the other hand, was independent of EGFR binding as well as its 
trypsin binding site, suggesting that there may be other interacting partners of SPINK1 to 
be identified. Being a secreted factor that is not only prognostic in breast cancer but also 
plays an important role in promoting cancer aggressiveness, SPINK1 is a tremendously 
attractive theragnostic target that could be used for both prognosis and targeted therapy in 




Tumor suppressor – SEMA6D 
Extensive cancer profiling has elucidated the complexities of solid tumors, 
exposing us to a huge amount of information about mutations, copy number alterations, 
structural variations, epigenetic changes and aberrations in gene expression patterns in 
the cancer genome. Not only has this increased our understanding of the biology of 
cancers, it has also provided new insights into the heterogeneity of tumors, tissue 
specificity of different tumor types, and improved our understanding of the integration of 
biological pathways. Therefore we hoped to leverage on state-of-the-art cancer profiling 
technologies, such as SNP array, gPET and RNA-seq to identify novel tumor suppressor 
genes that have been “super hardwired” by the cancer genome to be silenced through 
multiple mechanisms, including structural variations as well as epigenetic modifications. 
By integrating comprehensive genomic data of a single breast cancer cell line, MCF-7, 
we identified 12 putative tumor suppressor genes that were located in these “super 
hardwired” regions of the breast cancer genome. In addition, we hypothesized that in the 
highly integrated network of genes in a cell, tumor suppressor genes could interact with 
each other and lead to a synergistic improvement of prognosis if overexpressed as a pair 
as compared to a single tumor suppressor gene alone. By using a pairwise association of 
randomly paired candidate tumor suppressor genes, we discovered that these candidate 
tumor suppressor genes interact largely amongst themselves in a highly integrated 
network, with SEMA6D possibly as the key tumor suppressor gene in this entire network 
of tumor suppressor genes. Although some other semaphorins have also been discovered 
recently to be frequently deleted and silenced in cancer, we show that SEMA6D remains 
to be the only semaphorin that is strongly associated with good patient prognosis in breast 
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cancer. In vitro studies show that the re-introduction of functional SEMA6D is 
detrimental to breast cancer cells, resulting in cell death when active SEMA6D is 
expressed in the cells. Taken together, the presence of SEMA6D in tumor cells may be 
crucial in the prevention of cancer progression.  
 
Concluding remarks 
In this thesis, I described two parallel strategies that make use of genomic 
computational methods in the discovery of novel oncogenes and tumor suppressor genes 
in human breast cancer. The work on oncogene discovery led to a protein that plays a 
critical role in key processes in cancer progression, which could at the same time be 
attenuated with small molecule inhibitors, making it a good potential therapeutic target. 
Through the complementary work on SEMA6D, not only was a novel tumor suppressor 
associated with survival and cellular apoptosis discovered, but more importantly it 
demonstrates a proof-of-principle example by which novel tumor suppressor genes can 
be discovered simply by integrating comprehensive datasets of a single cell line, without 
the need for huge tumor datasets nor matched normal controls.  
To bring this work forward, mechanisms of action of SPINK1 and SEMA6D need 
to be further elucidated. The direct binding partner(s) of SPINK1 could be the key to 
understanding how SPINK1 regulates Bcl-2 and caspase-3 levels to result in drug 
resistance. Microarray or even comprehensive mutation experiments could also help to 
explain the bifurcation of SPINK1 pathways leading to drug resistance as well as 
induction of invasion. Similarly, downstream signaling pathways of SEMA6D need to be 
figured out, either by co-immunoprecipitation or directed knockdown experiments. A 
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comprehensive analysis of the mechanistic actions of both SPINK1 and SEMA6D may 
potentially enhance the efficacy and reduce undesirable side effects of targeting SPINK1 
























Materials and Methods 
Microarray data and tumor samples.  
Ten previously described breast cancer microarray datasets were used in this study, and 
all expression profiles were generated using the Affymetrix U133A and U133B 
Genechips as described in the original publications (55-58, 66, 68-70, 114, 115). All 
Affymetrix CEL files were retrieved from the Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/), normalized using the MAS5.0 global mean method 
(55), and probe set signal intensities were natural log transformed and scaled by adjusting 
the mean intensity to a target signal value of log 500. To remove cohort-dependent array 
biases, arrays within each cohort were mean-centered prior to combining them into one 
dataset. Meta-analysis on the association of SPINK1 expression with DMFS was 
performed using Partek.  
 
Mega Cohort analysis.  
SPINK1 expression characteristics were analyzed in breast cancer using an integrated 
“super cohort” of 2,116 breast tumors profiled using Affymetrix GeneChip technology. 
The super cohort is comprised of fifteen distinct breast cancer cohorts for which 
corresponding microarray data and clinical annotation were publicly accessible from 
microarray databases including the Gene Expression Omnibus (National Center for 
Biotechnology Information, USA), ArrayExpress (European Bioinformatics Institute, UK) 
and caArray (National Cancer Institute, NIH, USA) (55, 56, 67-69, 114-121). General 
cohort details and literature references are presented in Table 3.1. In all cases, raw data 
(CEL files) were pre-processed and normalized using the R software package (122) and 
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library files provided via the Bioconductor project (123).   In order to preserve a 
consistent normalization strategy across all cohorts, raw data were MAS5.0 normalized 
on a per-cohort basis using the justMAS function in the simpleaffy library from 
Bioconductor (no background correction, target intensity of 600). The specific array 
platforms employed here were the HG-U133A, HG-U133plus2 and HG-U113A2 gene 
chips. To ensure equal information content from each chip type, only probe sets common 
to all chip types were utilized in subsequent analysis.  This resulted in the use of 22,268 
probe sets that were common to all microarrays in all cohorts.  Cross-cohort batch effects 
were corrected using the COMBAT empirical Bayes method (124). Of the initial 2,116 
tumor profiles, 2034 represent primary invasive breast cancers with no exposure to 
neoadjuvant therapy prior to array analysis. Of these, 1954 cases are annotated with 
distant metastasis-free survival (DMFS) time and event. Of note, other clinical annotation 
such as treatment type, estrogen receptor status, nodal status, tumor size, histologic grade 
and patient age are available for the majority of cases. Intrinsic subtypes were assigned to 
samples using the Single Sample Predictor (SSP) algorithm described by Hu et al. (125) 
and utilized by Fan et al. (126). Affymetrix probe sets were matched to the genes 
comprising the SSP centroids using UniGene annotation. Prior to batch correction, the 
expression data for each gene were mean centered, and Spearman correlation was used to 
find the centroid most closely associated with each tumor sample. In cases where a 
correlation greater than 0.1 was not achieved with at least one centroid, a subtype was not 





Cell lines and stable overexpression.  
Human mammary cell lines, BT-549, MCF10A, MCF-7 and MDA-MB-231 were 
obtained from American Type Culture Collection (ATCC) and maintained at 37°C with 5% 
CO2 with growth medium recommended by ATCC. Full-length SPINK1 was 
commercially bought (Invitrogen:IOH10627), and a 3’ 6XHis Tag added to it via PCR, 
(SPINK1-F 5’ATGAAGGTAACAGGCATCTTTCTTCTCAGTGCCTT3’, SPINK1-H3-
R2 5’TCAGTGATGATGATGATGGTGGCAAGGCCCAGAT 3’). PCR products were 
cloned into pCR® 2.1-TOPO® vector (Invitrogen: K4510-20) followed by pcDNATM3.1(+) 
(Invitrogen: V790-20) via restriction sites NheI and EcoRI. Transient plasmid and RNAi 
transfection on breast cancer cell lines was carried out using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s protocol.  C2 siRNA (5’ 
CCAAGAUAUAUGACCCUGUTT 3’) gave the optimal knockdown of SPINK1, and 
was used in all other assays (C1-5’CCAAGGUUUUGAAAUCCCATT3’; C3-
5’GAGGCCAAAUGUUACAAUGTT3’). Stable colonies are selected by growing the 
transfected MCF-7 cells with G418 (Sigma) at 500ng/ul. Insect SF9 cells were obtained 
from BD Biosciences and maintained in Grace’s insect media (Invitrogen) supplemented 
with fungizone (Invitrogen) and 10% FBS. SPINK1 with a 3’ 6XHis tag was cloned into 
pPK30x vector, and infected into SF9 cells with baculovirus (BD Biosciences) according 
to the manufacturer’s protocol. 32D cells were purchased from ATCC and cultured as 
recommended by ATCC. 32D-EGFR and 32D-vector cells were a gift from Dr Yi-Rong 





Cell proliferation, anchorage-independent growth assay and apoptosis assays.  
Cells were transfected with SPINK1 siRNA at 100nM for 48hours. Cells were plated at a 
density of 5000 cells/well in 96-well plates, and cell proliferation was measured at 
various time points in quadruplicate using WST-1 (Roche: 11644807001) or BrDU 
(CalBiochem: QIA58) according to the manufacturer’s protocol. P-values were obtained 
by doing a 2-tailed t-test comparing proliferation rates between loss of gene and 
scrambled control. To test the effect of SPINK1 on anchorage-independent colony 
formation, cells were suspended in 250ul of 0.3% agar (Sigma) dissolved in complete 
medium containing 25% FBS, and plated in quadruplicate in 24-well plates pre-coated 
with 500ul of 0.6% agar base. Colony forming efficiency was examined 21 days or more 
after plating by staining with Iodonitrotetrazolium chloride (Sigma). Colonies of 
size >50um were counted using Leica QWin software. For the apoptosis PARP and 
Caspase-3 assay, 5000 cells were plated into each well in a 96-well plate. 5-fluorouracil 
was then added for a period of 24 hours. Cells were fixed and blocked with goat serum. 
Antibodies anti-cleaved PARP (BD: 552596), anti-active caspase3 (BD:559565), goat 
anti-mouse IgG Alexa 488 (Invitrogen: A21121) and goat anti-rabbit IgG Alexa 647 
(Invitrogen: 21244) were used for staining. TUNEL assay was carried out according to 
the kit instructions (Roche: 12156792910). 
 
In vitro invasion and migration.  
Transwell migration and invasion assays were performed using Falcon FluoroBlok 24-
Multiwell inserts (BD Biosciences) with 8 µm pores. For invasion assays, the inserts 
were coated with 20 µg Matrigel (BD Biosciences) in 80 µL serum-free growth medium. 
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For both assays, 30000 cells in 200 µL serum-free growth medium were loaded into each 
transwell insert with 750 µL complete growth medium or conditioned medium (CM, see 
below)  in the lower chamber. After 24 hours, cells that had migrated or invaded through 
the pores of the inserts were fixed with 3.7% formaldehyde, stained with 2.5 µg/mL 
Hoechst 33342 (Invitrogen) for 15 mins, washed with PBS and counted using the Target 
Activation Bioapplication on an ArrayScan VTI (Cellomics). Field size was 1 mm2. For 
both invasion and migration assays, experiments were performed with 4-fold replication 
and 10 fields were scanned per experiment.  
 
In vivo mouse xenograft assay.  
0.5x10^6 MDA-MB-231 cells stably overexpressing SPINK1 or empty vector were 
resuspended in 300ul of PBS and injected into the tail vein of Balb/c nude mice 12 weeks 
old. 4 mice were injected per cell line. Mice were euthanized 12 weeks later and lung 
sections were stained with hematoxylin and eosin. IACUC protocol #070256 was 
approved by the Biological Resource Centre, Agency of Science, Technology and 
Research. 
 
Conditioned Media, Neutralizing antibody and Western blot analysis.  
8-10ml of serum-free DMEM was added to each 15cm plate of MCF-7 cells 
overexpressing SPINK1 (Figure 3.4, clone 9) Twenty four hours later, CM is collected, 
centrifuged for 5 minutes at 800rpm at 4oC. The CM is then warmed to 37oC before use. 
For SF9 cells, the cells were infected with virus at the optimal titre. 3 days later, 
conditioned media is collected and centrifuged for 3 minutes at 1000rpm at 4oC to 
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remove the cells. For western blot analysis, CM was concentrated at least 30 times via the 
Amicon Ultra-15 centrifugal filter device from Millipore. For western blot analysis, 
whole cell lysates were prepared using RIPA buffer. The proteins were separated by 
SDS-PAGE and transferred to 0.2µm PVDF membrane (Biorad). SPINK1 antibody 
(MoBiTec: PSKAN2-0100) was used to probe the membrane at 500 times dilution, and 
antibody-protein complex was detected by HRP-conjugated antibodies and ECL 
(Amersham Biosciences). The same antibody was used for immunoneutralizing 
experiments. CM was pre-incubated with the antibody at 50 times dilution at room 
temperature for 2 hours before use.  
 
Immunohistochemistry and immunofluorescence.  
Tissue array slides were purchased from Biomax. Inc (BR1502, BN8013 and BN481), 
and Tissue microarray (TMA) blocks containing cores from 98 breast cancer patients 
were constructed as described previously (127, 128) under institutional ethics 
committee’s approval for the tissue array program (NUS-IRB 05-017).Staining was done 
with anti-SPINK1 monoclonal antibody (MoBiTec: PSKAN2-0100) at a dilution of 
1:1000 for immunohistochemistry and 1:50 for immunofluorescence. Other antibodies 
used for immunofluorescence include anti-His (Delta Biolabs), Alexa 488 goat anti-
mouse and Alexa 647 goat anti-rabbit (Invitrogen) at a dilution of 1:500. The Ariol SL-50 
is a commercial image analysis platform that utilizes an Olympus microscope with 
motorized stage and autofocus capabilities to digitize the TMA slides. Each slide was 
scanned at 20x objective with three filters: red, green and blue (RGB). The Ariol software 
then converted these RGB-channel scans into colour reconstructions for image analysis. 
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For SPINK1 expression, the Ariol analytical algorithm was trained using the positive 
controls. The positivity of the SPINK1 expression was initially confirmed by two senior 
pathologists (BP and MST).  The training of the Ariol algorithm was then performed by a 
pathological assistant (OCW) to ensure that stromal matrix and adipose cells are excluded 
from the image analysis. The training of the algorithm thus allowed more precise 
calculation of the percentage of positive tumour cells. After the initial program training, 
the rest of the analysis was performed without human supervision. Absolute values of 
expression were subsequently provided by the software for all the TMA cores. A random 
sample check was conducted at the end of the analysis to determine the accuracy of the 
Ariol algorithm. Previously, we have reported a high level of concordance (kappa 
value >0.9) between the Ariol scoring and human observer scoring methods for 
immunohistochemistry in a technical journal (129). The positivity of SPINK expression 
was determined by rank-transforming all the positive scores of SPINK1 expression into 
two groups based on a 50th percentile cutoff. All statistical analyses were performed 
using the SPSS package.  
 
RTH and CN loss analysis from Illumina SNP array data.  
Genomic DNA extracted from MCF7 cells was analyzed on Illumina Human 1M-Duo 
DNA Analysis BeadChip (Illumina Inc.) according to manufacturer’s protocol. Raw 
signals were processed using Illumina’s BeadStudioTM Data Analysis Software (version 
3.2) Genotyping Module (Illumina Inc.) together with an additional plugin called 
OverUnder(95) (version 3.9), which determines genomic copy number from 
heterogeneous tumor tissues by incorporating log R ratio (LRR=signal intensity) and B 
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allele frequency (BAF=allelic frequency) values. OverUnder’s default settings were used, 
where window length equals to 101. OverUnder estimated the copy number values 
corrected for MCF7’s aneuploidy by determining absolute copy number instead of copy 
number relative to DNA index. By using BeadStudio’s Genome Viewer (Illumina Inc.), 
we visually inspected the copy number graphs as well as LRR and BAF graphs across the 
chromosomes to find RTH or a copy number loss. Regions with a baseline copy number, 
a normal or increased LRR but without heterozygous SNPs are interpreted as RTH 
regions, whereas regions with decreased copy number and LRR as compared to the rest 
of the chromosome are interpreted as copy number loss.   
 
gPET and RNA-seq.  
Using the ABI SOLiD platform, RNA-sequencing (RNA-seq) and genome-wide PET 
(gPET) were done on the MCF-7 RNA and gDNA respectively. SOLiD BioScope 
version 1.0.1 Whole Transcriptome Analysis was then used for the analysis of the 
samples.  
 
Flow Cytometry.  
MCF7-TetOn cells were transfected with SEMA6D.6/pTRE-GFP or empty vector pTRE-
GFP and stably selected using 0.05ug/ml hygromycin. Stable cells were then cultured in 
the presence of doxocycline (1ug/ml) for a week. Cells were then sorted using the BD 
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